Non-invasive and minimally invasive denervation methods and systems for performing the same

Information

  • Patent Grant
  • 9649154
  • Patent Number
    9,649,154
  • Date Filed
    Friday, November 14, 2014
    2 years ago
  • Date Issued
    Tuesday, May 16, 2017
    5 months ago
Abstract
A system and method can be used to denervate at least a portion of a bronchial tree. An energy emitter of an instrument is percutaneously delivered to a treatment site and outputs energy to damage nerve tissue of the bronchial tree. The denervation procedure can be performed without damaging non-targeted tissue. Minimally invasive methods can be used to open airways to improve lung function in subjects with COPD, asthma, or the like. Different sections of the bronchial tree can be denervated while leaving airways intact to reduce recovery times.
Description
BACKGROUND

Technical Field


The present invention generally relates to non-invasive and minimally invasive denervation methods and systems and apparatuses for performing those methods.


Description of the Related Art


Pulmonary diseases may cause a wide range of problems that adversely affect performance of the lungs. Pulmonary diseases, such as asthma and chronic obstructive pulmonary disease (“COPD”), may lead to increased airflow resistance in the lungs. Mortality, health-related costs, and the size of the population having adverse effects due to pulmonary diseases are all substantial. These diseases often adversely affect quality of life. Symptoms are varied and often include cough, breathlessness, and wheeze. In COPD, for example, breathlessness may be noticed when performing somewhat strenuous activities, such as running, jogging, brisk walking, etc. As the disease progresses, breathlessness may be noticed when performing non-strenuous activities, such as walking. Over time, symptoms of COPD may occur with less and less effort until they are present all of the time, thereby severely limiting a person's ability to accomplish normal tasks.


Pulmonary diseases are often characterized by airway obstruction associated with blockage of an airway lumen, thickening of an airway wall, alteration of structures within or around the airway wall, or combinations thereof. Airway obstruction can significantly decrease the amount of gas exchanged in the lungs resulting in breathlessness. Blockage of an airway lumen can be caused by excessive intraluminal mucus or edema fluid, or both. Thickening of the airway wall may be attributable to excessive contraction of the airway smooth muscle, airway smooth muscle hypertrophy, mucous glands hypertrophy, inflammation, edema, or combinations thereof. Alteration of structures around the airway, such as destruction of the lung tissue itself, can lead to a loss of radial traction on the airway wall and subsequent narrowing of the airway.


Asthma can be characterized by contraction of airway smooth muscle, smooth muscle hypertrophy, excessive mucus production, mucous gland hypertrophy, and/or inflammation and swelling of airways. These abnormalities are the result of a complex interplay of local inflammatory cytokines (chemicals released locally by immune cells located in or near the airway wall), inhaled irritants (e.g., cold air, smoke, allergens, or other chemicals), systemic hormones (chemicals in the blood such as the anti-inflammatory cortisol and the stimulant epinephrine), local nervous system input (nerve cells contained completely within the airway wall that can produce local reflex stimulation of smooth muscle cells and mucous glands and can contribute to inflammation and edema), and the central nervous system input (nervous system signals from the brain to smooth muscle cells, mucous glands and inflammatory cells carried through the vagus nerve). These conditions often cause widespread temporary tissue alterations and initially reversible airflow obstruction that may ultimately lead to permanent tissue alteration and permanent airflow obstruction that make it difficult for the asthma sufferer to breathe. Asthma can further include acute episodes or attacks of additional airway narrowing via contraction of hyper-responsive airway smooth muscle that significantly increases airflow resistance. Asthma symptoms include recurrent episodes of breathlessness (e.g., shortness of breath or dyspnea), wheezing, chest tightness, and cough.


Emphysema is a type of COPD often characterized by the alteration of lung tissue surrounding or adjacent to the airways in the lungs. Emphysema can involve destruction of lung tissue (e.g., alveoli tissue such as the alveolar sacs) that leads to reduced gas exchange and reduced radial traction applied to the airway wall by the surrounding lung tissue. The destruction of alveoli tissue leaves areas of emphysematous lung with overly large airspaces that are devoid of alveolar walls and alveolar capillaries and are thereby ineffective at gas exchange. Air becomes “trapped” in these larger airspaces. This “trapped” air may cause over-inflation of the lung, and in the confines of the chest restricts the in-flow of oxygen rich air and the proper function of healthier tissue. This results in significant breathlessness and may lead to low oxygen levels and high carbon dioxide levels in the blood. This type of lung tissue destruction occurs as part of the normal aging process, even in healthy individuals. Unfortunately, exposure to chemicals or other substances (e.g., tobacco smoke) may significantly accelerate the rate of tissue damage or destruction. Breathlessness may be further increased by airway obstruction. The reduction of radial traction may cause the airway walls to become “floppy” such that the airway walls partially or fully collapse during exhalation. An individual with emphysema may be unable to deliver air out of their lungs due to this airway collapse and airway obstructions during exhalation.


Chronic bronchitis is a type of COPD that can be characterized by contraction of the airway smooth muscle, smooth muscle hypertrophy, excessive mucus production, mucous gland hypertrophy, and inflammation of airway walls. Like asthma, these abnormalities are the result of a complex interplay of local inflammatory cytokines, inhaled irritants, systemic hormones, local nervous system, and the central nervous system. Unlike asthma where respiratory obstruction may be largely reversible, the airway obstruction in chronic bronchitis is primarily chronic and permanent. It is often difficult for a chronic bronchitis sufferer to breathe because of chronic symptoms of shortness of breath, wheezing, and chest tightness, as well as a mucus producing cough.


Different techniques can be used to assess the severity and progression of pulmonary diseases. For example, pulmonary function tests, exercise capacity, and quality of life questionnaires are often used to evaluate subjects. Pulmonary function tests involve objective and reproducible measures of basic physiologic lung parameters, such as total airflow, lung volume, and gas exchange. Indices of pulmonary function tests used for the assessment of obstructive pulmonary diseases include the forced expiratory volume in 1 second (FEV1), the forced vital capacity (FVC), the ratio of the FEV1 to FVC, the total lung capacity (TLC), airway resistance and the testing of arterial blood gases. The FEV1 is the volume of air a patient can exhale during the first second of a forceful exhalation which starts with the lungs completely filled with air. The FEV1 is also the average flow that occurs during the first second of a forceful exhalation. This parameter may be used to evaluate and determine the presence and impact of any airway obstruction. The FVC is the total volume of air a patient can exhale during a forceful exhalation that starts with the lungs completely filled with air. The FEV1/FVC is the fraction of all the air that can be exhaled during a forceful exhalation during the first second. A FEV1/FVC ratio less than 0.7 after the administration of at least one bronchodilator defines the presence of COPD. The TLC is the total amount of air within the lungs when the lungs are completely filled and may increase when air becomes trapped within the lungs of patients with obstructive lung disease. Airway resistance is defined as the pressure gradient between the alveoli and the mouth to the rate of air flow between the alveoli and the mouth. Similarly, resistance of a given airway is defined as the ratio of the pressure gradient across the given airway to the flow of air through the airway. Arterial blood gases tests measure the amount of oxygen and the amount of carbon dioxide in the blood and are the most direct method for assessing the ability of the lungs and respiratory system to bring oxygen from the air into the blood and to get carbon dioxide from the blood out of the body.


Exercise capacity tests are objective and reproducible measures of a patient's ability to perform activities. A six minute walk test (6 MWT) is an exercise capacity test in which a patient walks as far as possible over a flat surface in 6 minutes. Another exercise capacity test involves measuring the maximum exercise capacity of a patient. For example, a physician can measure the amount of power the patient can produce while on a cycle ergometer. The patient can breathe 30 percent oxygen and the work load can increase by 5-10 watts every 3 minutes.


Quality of life questionnaires assess a patient's overall health and well being. The St. George's Respiratory Questionnaire is a quality of life questionnaire that includes 75 questions designed to measure the impact of obstructive lung disease on overall health, daily life, and perceived well-being. The efficacy of a treatment for pulmonary diseases can be evaluated using pulmonary function tests, exercise capacity tests, and/or questionnaires. A treatment program can be modified based on the results from these tests and/or questionnaires.


Treatments, such as bronchial thermoplasty, involve destroying smooth muscle tone by ablating the airway wall in a multitude of bronchial branches within the lung thereby eliminating both smooth muscles and nerves in the airway walls of the lung. The treated airways are unable to respond favorably to inhaled irritants, systemic hormones, and both local and central nervous system input. Unfortunately, this destruction of smooth muscle tone and nerves in the airway wall may therefore adversely affect lung performance. For example, inhaled irritants, such as smoke or other noxious substances, normally stimulate lung irritant receptors to produce coughing and contracting of airway smooth muscle. Elimination of nerves in the airway walls removes both local nerve function and central nervous input, thereby eliminating the lung's ability to expel noxious substances with a forceful cough. Elimination of airway smooth muscle tone may eliminate the airway's ability to constrict, thereby allowing deeper penetration of unwanted substances, such as noxious substances, into the lung.


Both asthma and COPD are serious diseases with growing numbers of sufferers. Current management techniques, which include prescription drugs, are neither completely successful nor free from side effects. Additionally, many patients do not comply with their drug prescription dosage regiment. Accordingly, it would be desirable to provide a treatment which improves resistance to airflow without the need for patient compliance.


BRIEF SUMMARY

Some embodiments are directed to non-invasive or minimally invasive denervation procedures. The denervation procedures can be performed without causing trauma that results in significant recovery periods. Non-invasive denervation methods can involve delivering energy from energy sources positioned external to the subject. The energy is aimed at targeted tissue to minimize, limit, or substantially eliminate appreciable damage to non-targeted tissue. Minimally invasive denervation procedures can involve percutaneously delivering an instrument.


Denervation of hollow organs, such as the lung bronchus, can be due to the creation of lesions with radiofrequency ablation that are of a sufficient depth when generated on the outside of the organ to penetrate the adventitial tissue layers where nerve trunks are anatomically located. In the example of lung denervation, ablating nerve trunks along the outside of both the right and left main bronchi effectively disconnects airway smooth muscle which lines the inside of the lung airways and mucus producing glands located with the airways from the vagus nerve. When this occurs, airway smooth muscle relaxes and mucus production is decreased. Nervous system mediated inflammation and edema will decrease as well. These changes reduce airway obstruction for subjects with COPD, asthma, or the like. Reduced airway obstruction makes breathing easier which improves the subject's quality of life and health status. Tests and questionnaires can be used to evaluate and monitor the subject's health.


Some embodiments are directed to a percutaneously deliverable apparatus capable of performing a denervation procedure. The apparatus can ablate targeted nerve tissue to denervate at least a portion of a lung. A minimally invasive access device can be used to percutaneously deliver the apparatus and can be a needle, a trocar, a robotic catheter, a mediastinoscope, a port, or a thoracoscope. Direct or remote visualization techniques (e.g., ultrasound guidance, endoscopy, radiologic guidance, etc.) can be used to position the apparatus.


The apparatus can be an instrument insertable directly into a hollow organ (e.g., through the mouth and into the esophagus or stomach) or inserted through the instrument channel of an endoscope (e.g., gastroscope, esophagoscope, or the like). The instrument has a flexible elongate shaft that carries one or more ablation elements. The ablation elements can be energy emitters, such as electrodes. The apparatus can be delivered through an opening in the subject's chest. The instrument can be brought into direct contact with the outer surface of the bronchial tree or lung while extending through the hollow organ.


The apparatus can be an instrument insertable directly into a large peripheral artery (e.g., femoral artery, brachial artery, or the like) and advanced through the arterial tree, into the aorta, and then into one or more bronchial arteries traveling along the main stem bronchi. The instrument has a flexible elongate shaft that carries one or more ablation elements. The ablation elements can be energy emitters, such as electrodes. The bronchial arteries are often located in close proximity to the vagus nerve trunks traveling along the outside of the bronchial tree. Placement of the instrument in one or more bronchial arteries brings the instrument with its ablation elements into close proximity to the vagus nerve trunks traveling along the outside of the bronchial tree. Advancement of the instrument and placement in the bronchial arteries can be guided by a variety of imaging modalities (e.g., fluoroscopy, ultrasound, CT scans, or the like).


In some embodiments, an instrument has an activatable section capable of intimately contacting a surface of an airway (either an outer surface or an inner surface). The activatable section can include one or more selectively activatable energy emitters, ablation elements, or the like. The activatable section can preferentially treat the posterior portion of the main lung airways or other targeted region(s) of airways.


A system for treating a subject includes an extraluminal elongate assembly dimensioned to move around the outside of the airway of a bronchial tree and an access device. The elongate assembly is adapted to attenuate signals transmitted by nerve tissue, such as nerve tissue of nerve trunks, while not irreversibly damaging adjacent anatomical structures. The elongate assembly can include at least one ablation element, which includes one or more electrodes operable to output radiofrequency energy.


Some methods involve minimally invasive denervation of at least a portion of a lung. The method comprises damaging nerve tissue of a first main bronchus to substantially prevent nervous system signals from traveling to most or substantially all distal bronchial branches connected to the first main bronchus. The nerve tissue, in certain embodiments, is positioned between a trachea and a lung through which the bronchial branches extend. The airway can remain intact while the nerve tissue is damaged.


The method, in some embodiments, further includes damaging nerve tissue of a second main bronchus to substantially prevent nervous system signals from traveling to most or substantially all distal bronchial branches connected to the second main bronchus. An apparatus used to damage the nerve tissue can be percutaneously delivered with the assistance of sonographic guidance, radiologic guidance, robotic guidance, mediastinoscopic guidance, thoracoscopic guidance, or other minimally invasive surgery visualization techniques.


In some embodiments, a method for treating a subject includes moving a tip of an instrument through at least a portion of a subject's skin to position the instrument next to nerve tissue. A desired amount of nerve tissue can then be damaged using the instrument. Some methods include damaging nerve tissue along a right main bronchus and ablating nerve tissue along the left main bronchus to denervate a significant portion of the bronchial tree. In other embodiments, denervating a portion of the bronchial tree comprises destroying at least one nerve trunk at a position that is within at least one of the left and right lung. The denervation process, in some embodiments, is performed without permanently damaging other tissue structures. In some denervation procedures, substantially all of the nerve trunks extending along a tubular section of an airway are damaged to prevent substantially all nervous system signals transmitted along the airway from traveling past the denervated portion without destroying the airway.


In yet other embodiments, a method for denervating a bronchial tree of a subject includes moving an energy emitter of an instrument through the subject's skin. The energy emitter is positioned proximate to an airway. Nerve tissue of the bronchial tree is damaged using the energy emitter while the energy emitter is positioned outside of the airway. The energy emitter can output a sufficient amount of at least one of radiofrequency energy, microwave energy, radiation energy, high intensity focused ultrasound energy (HIFU), thermal energy, or combinations thereof to damage the nerve tissue. In radiofrequency ablation, the instrument may cool and protect nontargeted tissue. High intensity focused ultrasound energy can be delivered to specific targeted tissue to mitigate damage of nontargeted tissue. The instrument is removed from the subject, leaving the airway intact.


Non-invasive denervation methods can be used to denervate a subject's lungs. An external energy source can deliver energy to targeted tissue to form lesions. The lesions can be formed at a depth of 1 mm to 2 mm along an airway to insure that a nerve trunk is destroyed without destroying the entire airway wall.


A method in some embodiments comprises moving a distal section of an instrument through a subject's skin. Most of a bronchial tree is denervated using the instrument to substantially prevent nervous system signals from traveling to substantially all branches of the bronchial tree. The distal section can be percutaneously delivered to minimize trauma and reduce recovery time. The method can be performed without severing airways, removing airways, or otherwise damaging the entire circumference of the denervated airway. In some embodiments, the entire procedure is performed without severing the entire airway. The airway can continue to function after the procedure.


A denervation method includes moving an energy emitter of an instrument through the subject's skin. Nerve tissue is altered (e.g., damaged, ablated, etc.) using energy from the energy emitter while the energy emitter is positioned outside of an airway or organ. The instrument is removed from the subject without destroying the airway or organ. In certain embodiments, the airway remains intact through the entire denervation process such that the airway maintains the health of distal portions of the lung. The denervation method can be used to denervate one or both lungs.


In some embodiments, a distal section of an instrument is wrapped around an airway to position at least one energy emitter with respect to nerve tissue. The energy emitter can output energy to damage the nerve tissue. Visualization can be used to view the airway. In certain embodiments, the outside of the airway is visualized while performing an ablation procedure or positioning the energy emitter. Visualization can be achieved using at least one of a thoracoscope, an ultrasonic device, and a fluoroscopy system.


A wide range of different types of body structures can be treated using energy. Non-limiting exemplary body structures include airways, the trachea, esophagus, vessels (e.g., blood vessels), the urethra, or other targeted structures. In certain embodiments, an instrument is endovascularly positioned in a blood vessel to position a distal portion of the instrument proximate to an airway nerve or other target region. Energy is delivered from the instrument to damage the airway nerve such that nerve signals to the airway are attenuated.


In some embodiments, a method for denervating a bronchial tree or other body structure of a subject includes moving an energy emitter of an instrument through the subject's skin. Nerve tissue is damaged using energy from the energy emitter while the energy emitter is positioned outside of the airway or body structure. In certain procedures, the instrument is removed from the subject without severing the entire airway. The procedure can be performed without puncturing the wall of the airway or body structure.


In yet other embodiments, a method for treating a subject comprises delivering emitting energy from an external energy source positioned outside of the subject's body through the subject's skin towards targeted nerve tissue of a bronchial tree. The nerve tissue is damaged using the energy while the external energy source is outside the subject's body. The external energy source can be placed against or spaced apart from the subject's skin.


In further embodiments, a method comprises percutaneously delivering a distal section of an instrument through a subject's skin such that the distal section is positioned to damage nerve tissue of a bronchial tree, blood vessel, or other body structure. In bronchial tree procedures, at least a portion of a bronchial tree in a subject's lung is denervated using the instrument to substantially prevent nervous system signals from traveling to a portion of the bronchial tree. In vascular procedures, a catheter is endovascularly positioned a in a blood vessel to position a distal portion of the catheter proximate to an airway nerve. The catheter is used to ablate nerve tissue.


In certain embodiments, an instrument is endovascularly positioned in a blood vessel (e.g., a bronchial artery or other vessel) to position a distal portion of the instrument proximate to an airway structure, such as a nerve. Energy is delivered from the instrument to damage the airway nerve such that nerve signals to the airway are attenuated. Other tissues can also be targeted.


One or more electrodes carried by the distal portion of the catheter can output radiofrequency energy or ultrasound energy. The electrode can be coupled to an outside surface of the distal portion or positioned within the distal portion. By delivering the energy, nerve signals can be attenuated so as to reduce constriction of the airway. In some embodiments, the constriction is permanently eliminated. In yet other procedures, nerve signals are attenuated so as to inhibit constriction of smooth muscle in the airway.


In other procedures, an instrument is passed through a subject's mouth and into the esophagus. The distal section of the instrument can be manipulated to position the distal section of the instrument proximate to the bronchial tree. In certain embodiments, the distal section can push against the wall of the esophagus to position an ablation assembly proximate to the left main bronchus or the right main bronchus. Without puncturing the esophagus wall, the ablation assembly can deliver energy to the nerve tissue with or without employing differential cooling. The ablation assembly can remain within the lumen of the esophagus throughout the ablation process.


The instruments can be passed through openings in the esophagus, the trachea, the left main bronchus and/or the right main bronchus. To pass an instrument out of the trachea, an opening can be formed in the wall of the trachea. The instrument can be moved through the opening and proximate to nerve tissue of an airway. The nerve tissue can be ablated while the instrument extends through the trachea wall and alongside the airway. In other procedures, a puncture can be formed along the left and/or right main bronchus. The instrument can be delivered through the opening and can wrap around the bronchus to destroy or ablate tissue.





BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

In the Figures, identical reference numbers identify similar elements or acts.



FIG. 1 is an illustration of lungs, blood vessels, and nerves near to and in the lungs.



FIG. 2 is an illustration of a system positioned to treat a left main bronchus.



FIG. 3 is a cross-sectional view of an airway of a bronchial tree taken along a line 3-3 of FIG. 2.



FIG. 4 is a cross-sectional view of a constricted airway and mucus is in an airway lumen and an instrument positioned next to the airway.



FIG. 5 is a cross-sectional view of an airway with an intraluminal instrument inside an airway and an instrument positioned outside the airway.



FIGS. 6-9 are side elevational views of distal sections of instruments.



FIG. 10 is an illustration of an instrument surrounding a left main bronchus.



FIG. 11 is a cross-sectional view of the left main bronchus of taken along a line 11-11 of FIG. 10.



FIG. 12 is an illustration of an external treatment system and a subject.





DETAILED DESCRIPTION


FIG. 1 illustrates human lungs 10 having a left lung 11 and a right lung 12. A trachea 20 extends downwardly from the nose and mouth and divides into a left main bronchus 21 and a right main bronchus 22. The left main bronchus 21 and right main bronchus 22 each branch to form lobar, segmental bronchi, and sub-segmental bronchi, which have successively smaller diameters and shorter lengths in the outward direction (i.e., the distal direction). A main pulmonary artery 30 originates at a right ventricle of the heart and passes in front of a lung root 24. At the lung root 24, the artery 30 branches into a left and right pulmonary artery, which in turn branch to form a network of branching blood vessels. These blood vessels can extend alongside airways of a bronchial tree 27. The bronchial tree 27 includes the left main bronchus 21, the right main bronchus 22, bronchioles, and alveoli. Vagus nerves 41, 42 extend alongside the trachea 20 and branch to form nerve trunks 45.


The left and right vagus nerves 41, 42 originate in the brainstem, pass through the neck, and descend through the chest on either side of the trachea 20. The vagus nerves 41, 42 spread out into nerve trunks 45 that include the anterior and posterior pulmonary plexuses that wrap around the trachea 20, the left main bronchus 21, and the right main bronchus 22. The nerve trunks 45 also extend along and outside of the branching airways of the bronchial tree 27. Nerve trunks 45 are the main stem of a nerve, comprising a bundle of nerve fibers bound together by a tough sheath of connective tissue.


The primary function of the lungs 10 is to exchange oxygen from air into the blood and to exchange carbon dioxide from the blood to the air. The process of gas exchange begins when oxygen rich air is pulled into the lungs 10. Contraction of the diaphragm and intercostal chest wall muscles cooperate to decrease the pressure within the chest to cause the oxygen rich air to flow through the airways of the lungs 10. For example, air passes through the mouth and nose, the trachea 20, then through the bronchial tree 27. The air is ultimately delivered to the alveolar air sacs for the gas exchange process.


Oxygen poor blood is pumped from the right side of the heart through the pulmonary artery 30 and is ultimately delivered to alveolar capillaries. This oxygen poor blood is rich in carbon dioxide waste. Thin semi-permeable membranes separate the oxygen poor blood in capillaries from the oxygen rich air in the alveoli. These capillaries wrap around and extend between the alveoli. Oxygen from the air diffuses through the membranes into the blood, and carbon dioxide from the blood diffuses through the membranes to the air in the alveoli. The newly oxygen enriched blood then flows from the alveolar capillaries through the branching blood vessels of the pulmonary venous system to the heart. The heart pumps the oxygen rich blood throughout the body. The oxygen spent air in the lung is exhaled when the diaphragm and intercostal muscles relax and the lungs and chest wall elastically return to the normal relaxed states. In this manner, air can flow through the branching bronchioles, the bronchi 21, 22, and the trachea 20 and is ultimately expelled through the mouth and nose.


A network of nerve tissue of the autonomic nervous system senses and regulates activity of the respiratory system and the vasculature system. Nerve tissue includes fibers that use chemical and electrical signals to transmit sensory and motor information from one body part to another. For example, the nerve tissue can transmit motor information in the form of nervous system input, such as a signal that causes contraction of muscles or other responses. The fibers can be made up of neurons. The nerve tissue can be surrounded by connective tissue, i.e., epineurium. The autonomic nervous system includes a sympathetic system and a parasympathetic system. The sympathetic nervous system is largely involved in “excitatory” functions during periods of stress. The parasympathetic nervous system is largely involved in “vegetative” functions during periods of energy conservation. The sympathetic and parasympathetic nervous systems are simultaneously active and generally have reciprocal effects on organ systems. While innervation of the blood vessels originates from both systems, innervation of the airways is largely parasympathetic in nature and travels between the lung and the brain in the right vagus nerve 42 and the left vagus nerve 41.



FIG. 2 shows a minimally invasive system 200 capable of treating the respiratory system to enhance lung function. The subject may suffer from COPD, asthma, or the like and, thus, the lungs 10 may perform poorly. To decrease air flow resistance to increase gas exchange, the system 200 can be used to perform a denervation procedure. A distal section 214 of an instrument 204 can affect nerve tissue, which can be part of a nerve trunk inside or outside of the lungs. The nerve tissue can be ablated to permanently dilate the airways and/or decrease airway mucus production or airway inflammation and edema.


The instrument 204 can be used to attenuate the transmission of signals traveling along the vagus nerves 41, 42 that cause or mediate muscle contractions, mucus 150 production, inflammation, edema, and the like. Attenuation can include, without limitation, hindering, limiting, blocking, and/or interrupting the transmission of signals. For example, the attenuation can include decreasing signal amplitude of nerve signals or weakening the transmission of nerve signals. Decreasing or stopping nervous system input to distal airways can alter airway smooth muscle tone, airway mucus production, airway inflammation, and the like, thereby controlling airflow into and out of the lungs 10. Decreasing or stopping sensory input from the airways and lungs to local effector cells or to the central nervous system can also decrease reflex bronchoconstriction, reflex mucous production, release of inflammatory mediators, and nervous system input to other cells in the lungs or organs in the body that may cause airway wall edema. In some embodiments, the nervous system input can be decreased to correspondingly decrease airway smooth muscle tone. In some embodiments, the airway mucus production can be decreased a sufficient amount to cause a substantial decrease in coughing and/or in airflow resistance. In some embodiments, the airway inflammation can be decreased a sufficient amount to cause a substantial decrease in airflow resistance and ongoing inflammatory injury to the airway wall. Signal attenuation may allow the smooth muscles to relax, prevent, limit, or substantially eliminate mucus production by mucous producing cells, and decrease inflammation. In this manner, healthy and/or diseased airways can be altered to adjust lung function. After treatment, various types of questionnaires or tests can be used to assess the subject's response to the treatment. If needed or desired, additional procedures can be performed to reduce the frequency of coughing, decrease breathlessness, decrease wheezing, and the like.


Main bronchi 21, 22 (i.e., airway generation 1) of FIGS. 1 and 2 can be treated to affect distal portions of the bronchial tree 27. In some embodiments, the left and right main bronchi 21, 22 are treated at locations along the left and right lung roots 24 and outside of the left and right lungs 11, 12. Treatment sites can be distal to where vagus nerve branches connect to the trachea and the main bronchi 21, 22 and proximal to the lungs 11, 12. A single treatment session involving two therapy applications can be used to treat most of or the entire bronchial tree 27. Substantially all of the bronchial branches extending into the lungs 11, 12 may be affected to provide a high level of therapeutic effectiveness. Because the bronchial arteries in the main bronchi 21, 22 have relatively large diameters and high heat sinking capacities, the bronchial arteries may be protected from unintended damage due to the treatment.


Nerve tissue distal to the main bronchi can also be treated, such as nerve tissue positioned outside the lung which run along the right or left main bronchi, the lobar bronchii, and bronchus intermedius. The intermediate bronchus is formed by a portion of the right main bronchus and includes origin of the middle and lower lobar bronchii. The distal section 214 can be positioned alongside higher generation airways (e.g., airway generations >2) to affect remote distal portions of the bronchial tree 27. Different procedures can be performed to denervate a portion of a lobe, an entire lobe, multiple lobes, or one lung or both lungs. In some embodiments, the lobar bronchi are treated to denervate lung lobes. For example, one or more treatment sites along a lobar bronchus may be targeted to denervate an entire lobe connected to that lobar bronchus. Left lobar bronchi can be treated to affect the left superior lobe and/or the left inferior lobe. Right lobar bronchi can be treated to affect the right superior lobe, the right middle lobe, and/or the right inferior lobe. Lobes can be treated concurrently or sequentially. In some embodiments, a physician can treat one lobe. Based on the effectiveness of the treatment, the physician can concurrently or sequentially treat additional lobe(s). In this manner, different isolated regions of the bronchial tree can be treated.


Each segmental bronchus may be treated by delivering energy to a single treatment site along each segmental bronchus. Nerve tissue of each segmental bronchus of the right lung can be destroyed. In some procedures, one to ten applications of energy can treat most of or substantially all of the right lung. Depending on the anatomical structure of the bronchial tree, segmental bronchi can often be denervated using one or two applications of energy.


Function of other tissue or anatomical features, such as the mucous glands, cilia, smooth muscle, body vessels (e.g., blood vessels), and the like can be maintained when nerve tissue is ablated. Nerve tissue includes nerve cells, nerve fibers, dendrites, and supporting tissue, such as neuroglia. Nerve cells transmit electrical impulses, and nerve fibers are prolonged axons that conduct the impulses. The electrical impulses are converted to chemical signals to communicate with effector cells or other nerve cells. By way of example, a portion of an airway of the bronchial tree 27 can be denervated to attenuate one or more nervous system signals transmitted by nerve tissue. Denervating can include damaging all of the nerve tissue of a section of a nerve trunk along an airway to stop substantially all the signals from traveling through the damaged section of the nerve trunk to more distal locations along the bronchial tree or from the bronchial tree more proximally to the central nervous system. Additionally, signals that travel along nerve fibers that go directly from sensory receptors (e.g., cough and irritant receptors) in the airway to nearby effector cells (e.g., postganglionic nerve cells, smooth muscle cells, mucous cells, inflammatory cells, and vascular cells) will also be stopped. If a plurality of nerve trunks extends along the airway, each nerve trunk can be damaged. As such, the nerve supply along a section of the bronchial tree can be cut off. When the signals are cut off, the distal airway smooth muscle can relax leading to airway dilation, mucous cells decrease mucous production, or inflammatory cells stop producing airway wall swelling and edema. These changes reduce airflow resistance so as to increase gas exchange in the lungs 10, thereby reducing, limiting, or substantially eliminating one or more symptoms, such as breathlessness, wheezing, chest tightness, and the like. Tissue surrounding or adjacent to the targeted nerve tissue may be affected but not permanently damaged. In some embodiments, for example, the bronchial blood vessels along the treated airway can deliver a similar amount of blood to bronchial wall tissues and the pulmonary blood vessels along the treated airway can deliver a similar amount of blood to the alveolar sacs at the distal regions of the bronchial tree 27 before and after treatment. These blood vessels can continue to transport blood to maintain sufficient gas exchange. In some embodiments, airway smooth muscle is not damaged to a significant extent. For example, a relatively small section of smooth muscle in an airway wall which does not appreciably impact respiratory function may be reversibly altered. If energy is used to destroy the nerve tissue outside of the airways, a therapeutically effective amount of energy does not reach a significant portion of the non-targeted smooth muscle tissue.


Any number of procedures can be performed on one or more of these nerve trunks to affect the portion of the lung associated with those nerve trunks. Because some of the nerve tissue in the network of nerve trunks coalesces into other nerves (e.g., nerves connected to the esophagus, nerves though the chest and into the abdomen, and the like), specific sites can be treated to minimize, limit, or substantially eliminate unwanted damage of other nerves. Some fibers of anterior and posterior pulmonary plexuses coalesce into small nerve trunks which extend along the outer surfaces of the trachea 20 and the branching bronchi and bronchioles as they travel outward into the lungs 10. Along the branching bronchi, these small nerve trunks continually ramify with each other and send fibers into the walls of the airways.


Referring to FIGS. 2 and 3, the distal section 214 is positioned within the chest outside of the airway 100. An activatable element in the form of an energy emitter 209 (illustrated in dashed line) is configured to damage nerve tissue 45, illustrated as a vagus nerve branch. Vagus nerve tissue includes efferent fibers and afferent fibers oriented parallel to one another within a nerve branch. The efferent nerve tissue transmits signals from the brain to airway effector cells, mostly airway smooth muscle cells and mucus producing cells. The afferent nerve tissue transmits signals from airway sensory receptors, which respond to irritants, and stretch to the brain. There is a constant, baseline tonic activity of the efferent vagus nerve tissues to the airways which causes a baseline level of smooth muscle contraction and mucous secretion.


The energy emitter 209 can ablate the efferent and/or the afferent tissues to control airway smooth muscle (e.g., innervate smooth muscle), mucous secretion, nervous mediated inflammation, and tissue fluid content (e.g., edema). The contraction of airway smooth muscle, excess mucous secretion, inflammation, and airway wall edema associated with pulmonary diseases often results in relatively high air flow resistance causing reduced gas exchange and decreased lung performance.


The instrument 204 can be delivered through a percutaneous opening in the chest, back, or other suitable location. Potential access locations include between the ribs in the chest, between the ribs in a para-sternal location, between the ribs along the back or side of the subject, from a subxiphoid location in the chest, or through the pre-sternal notch superior to the manubrium. As used herein, the term “percutaneous” and derivations thereof refer generally to medical procedures that involve accessing internal organs via an opening, such as a puncture or small incision in a subject's skin and may involve the use of an access apparatus, such as the access apparatus 210. The access apparatus 210 can be in the form of a trocar, a cannula, a port, a sleeve, or other less-invasive access device, along with an endoscope, a thoracoscope, or other visualization device. The distal section 214 can be relatively sharp to puncture and pass through tissue. A stylet can be positioned in a lumen in the instrument 204 and can have a relatively sharp tip to directly puncture the skin. After the stylet is inserted into the skin, the instrument 204 can be moved along the stylet through the user's skin into and between internal organs.


The instrument 204 may be visualized using fluoroscopy, computed tomography (CT), thoracoscopy, ultrasound, or other imaging modalities, and may have one or more markers (e.g., radiopaque marks), or dyes (e.g., radiopaque dyes), or other visual features. The visual features can help increase the instrument's visibility, including the instrument's radiopacity or ultrasonic visibility.


An instrument shaft 207 of FIG. 2 can be made of a generally flexible material to allow delivery along tortuous paths to remote and deep sites. The distal section 214 can be steered or otherwise manipulated using a steering assembly 208. The distal section 214 can be deflected laterally or shaped into a desired configuration to allow enhanced navigation around thoracic structures. To deliver energy to a treatment site, the distal section 214 can assume a treatment configuration. The treatment configuration can be a serpentine configuration, a helical configuration, a spiral configuration, a straight configuration, or the like. U.S. patent application Ser. No. 12/463,304, filed on May 8, 2009, and U.S. patent application Ser. No. 12/913,702, filed on Oct. 27, 2010, describe catheters and apparatuses that can assume these types of configurations and can be used to perform the methods disclosed herein. Each of these applications is incorporated by reference in its entirety. Conventional electrode catheters or ablation catheters can also be used to perform at least some methods disclosed herein.


To damage nerve tissue 45, the distal section 214 can be at different orientations, including transverse to the nerve trunk 45, generally parallel to the nerve trunk 45, or any other suitable orientation with respect to the airway 100. If the tissue is ablated using chemicals, the distal section 214 can puncture the nerve trunk 45 and deliver the agent directly to nerve tissue.


As used herein, the term “energy” is broadly construed to include, without limitation, thermal energy, cryogenic energy (e.g., cooling energy), electrical energy, acoustic energy (e.g., ultrasonic energy), microwave energy, radiofrequency energy, high voltage energy, mechanical energy, ionizing radiation, optical energy (e.g., light energy), and combinations thereof, as well as other types of energy suitable for treating tissue. The energy emitter 209 of FIG. 3 can include one or more electrodes (e.g., needle electrodes, bipolar electrodes, or monopolar electrodes) for outputting energy, such as ultrasound energy, radiofrequency (RF) energy, radiation, or the like. The electrodes can output a sufficient amount of RF energy to form a lesion at the periphery of the airway 100. To avoid damaging smooth muscle tissue, a lesion 219 (shown in phantom line in FIG. 3) can have a depth less than or equal to about 2 mm. In some embodiments, the lesion depth D can be less than about 1 mm to localize tissue damage. Thermal energy emitters 209 can be resistive heaters or thermally conducting elements. To treat tissue with microwave energy, the energy emitter 209 can include one or more microwave antennas. In optical embodiments, the energy emitter 209 includes one or more lenses or reflector(s) capable of outputting light delivered via one or more optical fibers. An external light source (e.g., a lamp, an array of light emitting diodes, or the like) can output light that is delivered through the shaft 207 to the energy emitter 209. In other embodiments, the energy emitter 209 is a light source, such as a light-emitting diode (LED) or laser diode. Photodynamic agents or light activatable agents can be used to ablate tissue. In yet other embodiments, the energy emitter 209 can include a dispenser (e.g., a nozzle, an orifice, etc.) for delivering a substance (e.g., a chemical agent, a high temperature fluid, a cutting jet, etc.) that kills or damages targeted tissue. Multiple emitters can be used sequentially or simultaneously to treat tissue. For example, an energy emitter in the form of a dispenser can mechanically damage surface tissue while another energy emitter outputs radiofrequency or microwave energy to destroy deep tissue.


For mechanical denervation, the distal section 214 can mechanically damage tissue by cutting, abrading, or tearing nerve tissue. A minimal amount of tissue adjacent to the nerve tissue 45 may also be damaged. The damaged non-targeted tissue can heal without any appreciable decrease in lung function. In embodiments, the distal section 214 comprises a morcellation device.


The distal section 214 can comprise one or more energy absorption devices for absorbing energy from a remote energy source. The remote energy source can be a microwave energy source, a radiofrequency energy source, an ultrasound energy source, or a radiation energy source and can be positioned outside the subject's body or located in another body structure, such as the esophagus, airway (trachea or bronchus), or elsewhere in the subject's body. The distal section 214 can be heated by the remote energy source to a sufficient temperature to damage targeted tissue. Additionally or alternatively, the element 209 can include a reflector to reflect energy from a remote energy source. The reflected energy can create a pattern (e.g., interference pattern) to control the amplitude of energy waves at the target site.


With continued reference to FIG. 2, the controller 221 can include one or more processors, microprocessors, digital signal processors (DSPs), field programmable gate arrays (FPGA), and/or application-specific integrated circuits (ASICs), memory devices, buses, power sources, and the like. For example, the controller 221 can include a processor in communication with one or more memory devices. Buses can link an internal or external power supply to the processor. The memories may take a variety of forms, including, for example, one or more buffers, registers, random access memories (RAMs), and/or read only memories (ROMs). The controller 221 may also include a display, such as a screen, and can be a closed loop system, whereby the power to the distal section 214 is controlled based upon feedback signals from one or more sensors 212 (see FIG. 3) configured to transmit (or send) one or more signals indicative of one or more tissue characteristics, energy distribution, tissue temperature, or any other measurable parameters of interest. Based on those readings, the controller 221 can then adjust operation of the distal section 214. By way of example, the controller 221 can control the amount of energy delivered from the energy source 217 (e.g., one or more batteries or other energy storage devices) to the energy emitter 209. The sensor 212 can be a temperature sensor. If the temperature of the peripheral tissue of the airway 100 becomes too hot, the distal section 214 can cool the tissue using one or more Peltier devices, cooling balloons, or other types of cooling features. Current sensors or voltage sensors 212 can be used to measure the tissue impedance. Alternatively, the controller 221 can be an open loop system wherein the operation is set by user input. For example, the system 200 may be set to a fixed power mode. It is contemplated that the system 200 can be repeatedly switched between a closed loop mode and an open loop mode to treat different types of sites.


The instrument 204 can also include any number of different types of visualization devices, such as cameras, optical fibers, lenses, or mirrors. Ultrasound or other types of energy-based viewing systems can be used to visualize deep targeted tissues. Surface tissues can be targeted using direct visualization while deeper tissues are subsequently targeted using ultrasound.



FIG. 4 shows a constricted, edematous and mucous filled airway 100 that can be dilated and can have mucous production and edema decreased by ablating the nerve tissue 45. As used herein, the term “ablate,” including variations thereof, refers, without limitation, to destroying or permanently damaging, injuring, or traumatizing tissue. For example, ablation may include localized tissue destruction, cell lysis, cell size reduction, necrosis, or combinations thereof. In the context of pulmonary ablation applications, the term “ablation” includes sufficiently altering nerve tissue properties to substantially block transmission of electrical signals through the ablated nerve tissue. Ablating all of the nerve trunks along the airway prevents nerve signals from traveling distally along the airway 100 and causes the smooth muscle 114 to relax to open the airway 100.


In RF ablation, RF energy causes heating of the nerve tissue 45 and, ultimately, the formation of the lesion 219. The nerve tissue is destroyed without removing a significant amount of airway tissue, if any, to preserve the integrity of the airway 100. The lesion 219 can be left in the body to avoid potential complications from removing airway tissue. The healthy airway wall 103 prevents gas escape across the airway wall 103. The smooth muscle and interior lining of the airway 100 can remain substantially undamaged to allow mucociliary transport and other bodily functions that are important to overall health. This reduces the recovery time and avoids or mitigates problems associated with surgical techniques of removing or cutting through the airway wall. In contrast to lung resection procedures in which entire airways are severed and removed, an intact denervated airway 100 can also ensure that distal regions of the lung continue to function.


Large lesions can extend through the airway wall and can be formed to destroy unwanted tissue (e.g., cancerous tissues) positioned along the inner surface. Differential cooling can be used to form lesions buried deep within the sidewall 103, spaced apart from the interior and exterior surfaces of the airway 100, or any other suitable location. U.S. patent application Ser. No. 12/463,304, filed on May 8, 2009, and U.S. patent application Ser. No. 12/913,702, filed on Oct. 27, 2010 discloses various catheters and differential cooling techniques. The instrument 204 can cool tissues to keep the nontargeted tissue below a temperature at which cell death occurs. In some embodiments, the distal section 214 has a cooling member (e.g., a cooling balloon) that absorbs thermal energy to keep nontargeted regions of the airway wall 103 at or below a desired temperature. The shape and size of lesions can also be adjusted as desired.


Natural body functions can help prevent, reduce, or limit tissue damage. If the bronchial artery branch 130 is heated, blood within the blood vessels 130 can absorb the thermal energy and can then carry the thermal energy away from the heated section of the branches 130. The lesion 219 can surround a region of the blood vessel 130 without destroying the vessel 130. After the treatment is performed, the bronchial artery branches 130 can continue to maintain the health of lung tissue.


The lesion depth D of FIG. 4 can be kept at or below a desired depth by controlling the amount of delivered energy. To avoid reaching smooth muscle 114, the depth D can be equal to or less than about 3 mm, 2 mm, or 1 mm. For thick airway walls, the lesion depth D can be equal to or less than about 3 mm. For medium size airway walls, the lesion depth D can be equal to or less than about 2 mm. In young children with thin airway walls, the lesion depth D can be equal to or less than about 1 mm. The lateral dimensions (e.g., width, length, etc.) of the lesion 219 can be adjusted to ensure that targeted tissue is ablated.



FIG. 5 shows a system that includes a pair of separately deliverable instruments 310, 312. The instrument 312 can be generally similar to the instrument 204 of FIGS. 2-4, unless indicated otherwise. The instrument 310 can be an intraluminal catheter deliverable through a lumen 101 defined by an inner surface 102 of the airway 100. The illustrated inner surface 102 is defined by a folded layer of epithelium 110 surrounded by stroma 112a. A layer of smooth muscle tissue 114 surrounds the stroma 112a. A layer of stroma 112b is between the muscle tissue 114 and connective tissue 124. Mucous glands 116, cartilage plates 118, blood vessels 120, and nerve fibers 122 are within the stroma layer 112b. Bronchial artery branches 130 and nerve trunks 45 are exterior to a wall 103 of the airway 100. The illustrated arteries 130 and nerve trunks 45 are within the connective tissue 124 surrounding the airway wall 103 and can be oriented generally parallel to the airway 100. In FIG. 1, for example, the nerve trunks 45 originate from the vagus nerves 41, 42 and extend along the airway 100 towards the air sacs. The nerve fibers 122 are in the airway wall 103 and extend from the nerve trunks 45 to the muscle tissue 114. Nervous system signals are transmitted from the nerve trunks 45 to the muscle 114 via the nerve fibers 122.


The instrument 310 can be delivered along the trachea, esophagus, or other body structure in the vicinity of the treatment site. For example, the instrument 310 can extend through one or more organs to position an energy emitter 314 proximate to the targeted tissue. Instruments 310, 312 can cooperate to treat the targeted tissue therebetween. The instrument 310 can cool interior regions of the airway wall 103 to cause the formation of the lesion 219 at the outer periphery of the airway wall 103. For radiofrequency ablation, the RF energy can travel between bipolar electrodes 314, 316. Tissue impedance causes heating that can reach sufficiently high temperatures to cause cell death. To protect non-targeted tissues (e.g., interior tissue), the instrument 310 can cool the airway to keep the nontargeted tissue below a temperature at which cell death occurs.


Thermal energy can be absorbed by the instrument 312 to keep the exterior regions of the airway wall 103 at or below a desired temperature. Both instruments 310, 312 can provide cooling to form lesions generally midway through the airway wall 103. The amount of energy delivered and cooling capacity provided by the instruments 310, 312 can be adjusted to shape and form lesions at different locations.


At least one of the instruments 310, 312 can be adapted to tunnel through tissue or between adjacent structures to allow it to reach the desired location, for example, along the bronchi. Additionally or alternatively, the instruments 310, 312 may be adapted to adhere to or slide smoothly along tissue or to be urged against a structure (e.g., trachea, esophagus, and/or bronchi) as the instrument is advanced.



FIG. 6 shows an instrument distal section 325 that includes a tissue-receiving region 324 and an energy emitter 326. The tissue-receiving region 324 has a concave surface 327 that generally matches a convex surface of an airway. A radius of curvature of the portion 324 can be approximately equal to the radius of curvature of the airway. When the distal section 325 is held against an airway, the energy emitter 326 can face targeted tissue.



FIG. 6A shows an instrument distal section 334 that includes an energy emitter 335 facing an airway 337. A distal tip 339 is shaped to keep the energy emitter 335 facing the airway 337 as the distal section 334 is moved distally, as indicated by an arrow 341. For example, the slope region 343 can help separate tissue 347 to facilitate distal movement of the distal section 334.


Referring to FIG. 7, an instrument distal section 330 includes a tissue-receiving surface 327 and an opposing guiding surface 329. The guiding surface 329 can slide smoothly along non-targeted tissue to facilitate advancement of the distal section 330. The curvature, contour, or slope of the guiding surface 329 can be selected to urge the tissue-receiving surface 327 against an anatomical structure. An energy emitter 342 (illustrated as a plurality of electrodes) can direct energy towards tissue received by the tissue-receiving surface 327. To position at least a portion of a nerve trunk in the surface 327, the tip 333 can be inserted between an airway and adjacent tissue.


A wide range of different types of guides can partially or completely surround a structure, such as the esophagus, trachea, or bronchus. Guides may include, without limitation, a plurality of arms (e.g., a pair of arms, a set of curved or straight arms, or the like), a ring (e.g., a split ring or a continuous ring), or the like. FIGS. 8, 8A, and 8B show embodiments of an instrument distal section 350 with a guide 352 capable of surrounding a generally tubular structure. An emitter 354 is positioned to deliver energy to a structure held by the guide 352. The distal section 350 can be moved along the airway using the guide 352. The guide 352 can be pulled off the airway and used to slide the distal section 350 along another airway or other anatomical structure.


The illustrated guide 352 is a split ring lying in an imaginary plane that is generally perpendicular to a longitudinal axis 361 of the distal section 350. To treat the main bronchus, resilient arms 353a, 353b can be moved away from each other to receive the bronchus. The arms 353a, 353b can snuggly hold the bronchus to allow atraumatic sliding. Surface 355a, 355b can slide smoothly along an airway or other body structure. In some embodiments, the guide 352 is pivotally coupled to the instrument shaft to allow the guide 352 to rotate as it moves along a structure.



FIG. 9 shows an instrument distal section 360 with guides in the form of openings 363. The openings 363 are circumferentially spaced about the periphery of a main body 365. A vacuum can be drawn through one or more of the openings 363 to hold the distal section 360 against tissue. In other embodiments, fluids can be delivered out of one or more of the openings 363 to push the distal section 360 in a desired direction.



FIG. 10 shows an instrument 400 with a distal section 412 wrapped around a left main bronchus. The distal section 412 can be configured to assume a helical shape or spiral shape. As shown in FIG. 11, energy emitters 414a-414n (collectively “414”) can deliver energy directly to the airway 100. An outer region 418 of the distal section 412 may not output energy to protect adjacent tissue. As such, the distal section 412 can effectively emit energy towards the airway 100. In other embodiments, the distal section 412 can output energy in all directions. A protective sleeve can be positioned over the applied distal section 412 to protect adjacent tissue. The sleeve can be made of an insulating material.


To treat the nerves 45, the electrodes 414c, 414j, 414k can be activated. The other electrodes 414 can remain inactive. In other embodiments, a continuous electrode can extend along the length of the distal section 414. The continuous electrode can be used to form a helical or spiral shaped lesion. In certain embodiments, the continuous electrode can have addressable sections to allow for selective ablation.


Airway cartilage rings or cartilage layers typically have a significantly larger electrical resistance than airway soft tissue (e.g., smooth muscle or connective tissue). Airway cartilage can impede the energy flow (e.g., electrical radiofrequency current flow) and makes the formation of therapeutic lesions to affect airway trunks challenging when the electrode is next to cartilage. The electrodes 414 can be positioned to avoid energy flow through cartilage. For example, the electrode 414 can be positioned between cartilage rings. Most or substantially all of the outputted energy can be delivered between the rings in some procedures. Tissue impedance can be measured to determine whether a particular electrode is positioned next to a cartilage ring, in an intercartilaginous space, or at another location.


Referring again to FIG. 10, the instrument 400 may have a lumen to receive a stylet to straighten and stiffen the preshaped distal section 412 during introduction. After insertion, the stylet can be withdrawn to allow the preshaped distal section 412 to assume a treatment configuration (e.g., a spiral configuration, a helical configuration, or the like). Alternatively, the distal section 412 may be relatively flexible and straight during introduction. A stylet having a shape corresponding to a desired shape may be inserted into the instrument 400 to impart the desired shape to the distal section 412. In a further embodiment, the instrument 400 may be shapeable or steerable using an actuator at its proximal end to allow it to be steered so as to surround the target tubular structure. Various steering mechanisms can be used, including, for example, one or more pull wires anchored to a distal tip at a point offset from the center line. The wire(s) can extend slidably through one or more lumens in the instrument 400 to the proximal end where they may be tensioned by an actuator so as to deflect the distal section 412.



FIG. 12 shows a system for non-invasively denervating a bronchial tree. An external energy source 500 is connected to an energy delivery system 510. The external energy source 500 can emit a beam of radiation to targeted tissue, such as nerve tissue. The beam of radiation can destroy the targeted tissue. The system can include, or be in the form of, a CyberKnife® Robotic Radiosurgery System from Accuray®, a TomoTherapy® radiation therapy system, or similar type of systems capable of targeting moving tissue, thereby mitigating or limiting damage to non-targeted tissue.


Beam radiation may be delivered from different remote locations to damage deep nerve tissue without damaging intervening tissues. The source of beam radiation may be a beam emitter 500 of an external beam radiotherapy system or a stereotactic radiation system 510. Because the lungs and bronchi move as the subject breathes, the system can be adapted to target moving tissues. By positioning the radiation beam emitter 500 at various locations relative to the patient's body 522, such systems may be used to deliver a radiation beam from various angles to the targeted nerve tissue. The dose of radiation given to intervening tissues may be insufficient to cause injury, but the total dose given to the target nerve tissue is high enough to damage (e.g., ablate) the targeted tissue.


Ultrasound can be used to damage targeted tissue. High intensity focused ultrasound may be used to target and damage the nerve tissue. The external energy source 500 can be a HIFU emission device. Alternatively, a catheter, an intra-luminal instrument, or other type of instrument for insertion into the body can include a HIFU emission device. By way of example, the element 209 of FIG. 3 can be a HIFU emission device. Such embodiments are well suited for delivery through another body structure, such as the esophagus or airway, to treat target tissue of an airway. The HIFU instrument may include ultrasound imaging capability to locate the targeted tissues. The HIFU instrument can emit a plurality of ultrasound “beams” from different angles toward the target tissues. The intensity of any one of the beams can be insufficient to damage intervening tissues. The beams can interfere at the target site and together have sufficient magnitude to damage the target nerve tissue.


The HIFU-based systems can be adapted to target moving tissues. For example, such systems may have a computer-controlled positioning system which receives input from an ultrasound or other imaging system and commands a positioning system in real time to maintain the HIFU device in a fixed position relative to the target structure.


Instruments disclosed herein may be entirely or partially controlled robotically or by a computer. Instruments may be attachable to a computer-controlled robotic manipulator which moves and steers the instruments. Robotic systems, such as the da Vinci® Surgical System from Intuitive Surgical or the Sensei Robotic Catheter system from Hansen Medical, Inc., or similar types of robotic systems, can be used. The instruments can have a proximal connector (e.g., an adaptor mechanism) that connects with a complementary fitting on the robotic system and links movable mechanisms of the instrument with control mechanisms in the robotic system. The instrument connector can also provide electrical couplings for wires leading to energy emitters, electrodes, microwave antennae, or other electrically powered devices. The instrument may further include sensor devices (e.g., temperature sensors, tissue impedance sensors, etc.) which are also coupled via the connector of the robotic system. The robotic system can include a control module that allows the physician to move and activate the denervation instrument while visualizing the location of the instrument within the chest, for example, using thoracoscopy, fluoroscopy, ultrasound, or other suitable visualization technology. The instrument may also be computer controlled, with or without robotic manipulation. A computer may receive feedback (e.g., sensory data) from sensors carried by the instrument or elsewhere to control positioning, power delivery, or other parameters of interest. For example, in energy-based denervation embodiments, a computer may be used to receive temperature data from temperature sensors of the instrument and to control power delivery to avoid overheating of tissue.


The instruments can access sites through blood vessels, as well as external to the organs. Robot surgery (including robotic catheter systems), natural orifice access methods, and minimally invasive access methods such as using trocar access methods and thoracoscopy have provided clinicians with access procedure locations within the human body and also minimized patient morbidity and complications due to surgery.


The assemblies, methods, and systems described herein can be used to affect tissue which is located on the outside of hollow organs, such as the lung, esophagus, nasal cavity, sinus, colon, vascular vessels and the like or other solid organs. Various types of activatable elements (e.g., energy emitters) can be utilized to output the energy. The activatable elements can be sufficiently small to facilitate percutaneous delivery to minimize or limit trauma to the patient.


The embodiments disclosed herein can treat the digestive system, nervous system, vascular system, or other systems. The treatment systems and its components disclosed herein can be used as an adjunct during another medical procedure, such as minimally invasive procedures, open procedures, semi-open procedures, or other surgical procedures (e.g., lung volume reduction surgery) that provide access to a desired target site. Various surgical procedures on the chest may provide access to lung tissue, the bronchial tree, or the like. Access techniques and procedures used to provide access to a target region can be performed by a surgeon and/or a robotic system. Those skilled in the art recognize that there are many different ways that a target region can be accessed. The various embodiments h such claims are entitled. Accordingly, the claims are not limited by the disclosure. described above can be combined to provide further embodiments. All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the Application Data Sheet are incorporated herein by reference, in their entirety. Aspects of the embodiments can be modified, if necessary to employ concepts of the various patents, applications and publications to provide yet further embodiments.


These and other changes can be made to the embodiments in light of the above-detailed description. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled. Accordingly, the claims are not limited by the disclosure.

Claims
  • 1. A system, comprising: a percutaneously and extraluminally deliverable denervation instrument including a flexible elongate shaft and an energy emitter disposed at a distal section of the flexible elongate shaft, the distal section being configured to be delivered percutaneously and extraluminally into a patient and positioned into contact with and forming a curved surface extending at least partially around an outer surface of an airway of a bronchial tree of the patient to position the energy emitter with respect to nerve tissue along the airway of the bronchial tree, wherein the energy emitter is positioned on an inner side of the curved surface,a controller configured to deliver energy from an energy source to the energy emitter so as to damage the nerve tissue along the airway of the bronchial tree of the patient while the energy emitter is positioned outside and adjacent the airway,wherein the distal section of the flexible elongate shaft further includes an outer shielding region on an outer side of the curved surface covering the energy emitter to protect adjacent non-target tissue from damage when energy is being delivered to the energy emitter.
  • 2. The system of claim 1, wherein the distal section of the flexible elongate shaft is configured to assume a helical shape about the outer surface of the airway.
  • 3. The system of claim 1, wherein the energy emitter comprises a plurality of electrodes configured to deliver energy directly to the airway.
  • 4. The system of claim 3, wherein the electrodes are selectively activatable.
  • 5. The system of claim 1, further comprising: an access device to percutaneously and extraluminally deliver the denervation instrument.
  • 6. The system of claim 5, wherein the access device comprises a needle, a trocar, a cannula, a port, a sleeve, an endoscope, a thoracoscope, or combinations thereof.
  • 7. A system, comprising: a percutaneously deliverable denervation instrument including a flexible elongate shaft and an energy emitter disposed at a distal section of the flexible elongate shaft;a guide means generally operably coupled to the flexible elongate shaft, the guide means being configured to be introduced percutaneously into a chest cavity of a patient and to guide the distal section of the flexible elongate shaft to at least partially surround an outer surface of an airway of a bronchial tree of a patient and to position the energy emitter with respect to nerve tissue along the airway of the bronchial tree, wherein the distal section is configured to form a curved surface extending a least partially around the outer surface of the airway, and the energy emitter is positioned on an inner side of the curved surface; anda controller configured to deliver energy from an energy source to the energy emitter so as to damage the nerve tissue along the airway of the patient while the energy emitter is positioned outside of the airway and while the guide is at least partially surrounding the airway,wherein the distal section of the flexible elongate shaft further includes an outer shielding region on an outer side of the curved surface covering the energy emitter to protect adjacent non-target tissue from damage when energy is being delivered to the energy emitter.
  • 8. The system of claim 7, wherein the guide means comprises a plurality of arms.
  • 9. The system of claim 8, wherein the plurality of arms are configured to be movable away from one another so as to receive the airway.
  • 10. The system of claim 7, wherein the guide means comprises a plurality of openings disposed in the distal end, and wherein the system is configured to draw a vacuum through one or more of the plurality of openings to position the energy emitter in a desired position.
  • 11. The system of claim 7, wherein the guide means comprises a ring or a split-ring.
  • 12. The system of claim 7, wherein the guide means is configured to be introduced into the chest cavity through intercostal space.
RELATED APPLICATIONS

This application is a continuation of application Ser. No. 12/944,666 filed Nov. 11, 2010, now U.S. Pat. No. 8,911,439, which claims the benefit of U.S. Provisional Application No. 61/260,350 filed Nov. 11, 2009, each of which is hereby fully incorporated herein by reference.

US Referenced Citations (1439)
Number Name Date Kind
612724 Hamilton Oct 1898 A
1155169 Starkweather Sep 1915 A
1207479 Bisgaard Dec 1916 A
1216183 Swingle Feb 1917 A
1695107 Kahl Dec 1928 A
2072346 Smith Mar 1937 A
2279714 Meyerhof et al. Apr 1942 A
3320957 Sokolik May 1967 A
3568659 Karnegis Mar 1971 A
3667476 Muller Jun 1972 A
3692029 Adair Sep 1972 A
3918449 Pistor Nov 1975 A
3946745 Hsiang-Lai et al. Mar 1976 A
3949743 Shanbrom Apr 1976 A
3995617 Watkins et al. Dec 1976 A
4078864 Howell Mar 1978 A
4095602 Leveen Jun 1978 A
4116589 Rishton Sep 1978 A
4129129 Amrine Dec 1978 A
4154246 LeVeen May 1979 A
4277168 Oku Jul 1981 A
4305402 Katims Dec 1981 A
4351330 Scarberry Sep 1982 A
4461283 Doi Jul 1984 A
4502490 Evans et al. Mar 1985 A
4503855 Maslanka Mar 1985 A
4503863 Katims Mar 1985 A
4512762 Spears Apr 1985 A
4522212 Gelinas et al. Jun 1985 A
4557272 Carr Dec 1985 A
4565200 Cosman Jan 1986 A
4567882 Heller Feb 1986 A
4573481 Bullara Mar 1986 A
4584998 McGrail Apr 1986 A
4612934 Borkan Sep 1986 A
4621642 Chen Nov 1986 A
4621882 Krumme Nov 1986 A
4625712 Wampler Dec 1986 A
4643186 Rosen et al. Feb 1987 A
4646737 Hussein et al. Mar 1987 A
4649924 Taccardi Mar 1987 A
4649935 Charmillot et al. Mar 1987 A
4658836 Turner Apr 1987 A
4674497 Ogasawara Jun 1987 A
4683890 Hewson Aug 1987 A
4704121 Moise Nov 1987 A
4706688 Don Michael et al. Nov 1987 A
4709698 Johnston et al. Dec 1987 A
4739759 Rexroth et al. Apr 1988 A
4754065 Levenson et al. Jun 1988 A
4754752 Ginsburg et al. Jul 1988 A
4765322 Charmillot et al. Aug 1988 A
4765959 Fukasawa Aug 1988 A
4767402 Kost et al. Aug 1988 A
4772112 Zider et al. Sep 1988 A
4773899 Spears Sep 1988 A
4779614 Moise Oct 1988 A
4784135 Blum et al. Nov 1988 A
4790305 Zoltan et al. Dec 1988 A
4799479 Spears Jan 1989 A
4802492 Grunstein Feb 1989 A
4808164 Hess Feb 1989 A
4817586 Wampler Apr 1989 A
4825871 Cansell May 1989 A
4827935 Geddes et al. May 1989 A
4846152 Wampler et al. Jul 1989 A
4862886 Clarke et al. Sep 1989 A
4881542 Schmidt et al. Nov 1989 A
4895557 Moise et al. Jan 1990 A
4902129 Siegmund et al. Feb 1990 A
4904472 Belardinelli et al. Feb 1990 A
4906229 Wampler Mar 1990 A
4907589 Cosman Mar 1990 A
4908012 Moise et al. Mar 1990 A
4920978 Colvin May 1990 A
4944722 Carriker et al. Jul 1990 A
4945910 Budyko et al. Aug 1990 A
4955377 Lennox et al. Sep 1990 A
4967765 Turner et al. Nov 1990 A
4969865 Hwang et al. Nov 1990 A
4976709 Sand Dec 1990 A
4985014 Orejola Jan 1991 A
4989604 Fang Feb 1991 A
4991603 Cohen et al. Feb 1991 A
4992474 Skidmore et al. Feb 1991 A
5005559 Blanco et al. Apr 1991 A
5007908 Rydell Apr 1991 A
5009636 Wortley et al. Apr 1991 A
5009936 Yamanaka et al. Apr 1991 A
5010892 Colvin et al. Apr 1991 A
5019075 Spears et al. May 1991 A
5027829 Larsen Jul 1991 A
5030645 Kollonitsch Jul 1991 A
5036848 Hewson Aug 1991 A
5053033 Clarke Oct 1991 A
5054486 Yamada Oct 1991 A
5056519 Vince Oct 1991 A
5056529 de Groot Oct 1991 A
5057107 Parins et al. Oct 1991 A
5074860 Gregory et al. Dec 1991 A
5078716 Doll Jan 1992 A
5084044 Quint Jan 1992 A
5096916 Skupin Mar 1992 A
5100388 Behl et al. Mar 1992 A
5100423 Fearnot Mar 1992 A
5103804 Abele et al. Apr 1992 A
5105826 Smits et al. Apr 1992 A
5106360 Ishiwara et al. Apr 1992 A
5107830 Younes Apr 1992 A
5107835 Thomas Apr 1992 A
5109846 Thomas May 1992 A
5114423 Kasprzyk et al. May 1992 A
5116864 March et al. May 1992 A
5117828 Metzger et al. Jun 1992 A
5123413 Hasegawa et al. Jun 1992 A
5126375 Skidmore et al. Jun 1992 A
5135480 Bannon et al. Aug 1992 A
5135517 McCoy Aug 1992 A
5139029 Fishman et al. Aug 1992 A
5151100 Abele et al. Sep 1992 A
5152286 Sitko et al. Oct 1992 A
5165420 Strickland Nov 1992 A
5167223 Koros et al. Dec 1992 A
5170802 Mehra Dec 1992 A
5170803 Hewson et al. Dec 1992 A
5174288 Bardy et al. Dec 1992 A
5188602 Nichols Feb 1993 A
5190540 Lee Mar 1993 A
5191883 Lennox et al. Mar 1993 A
5213576 Abiuso et al. May 1993 A
5215103 Desai Jun 1993 A
5224491 Mehra Jul 1993 A
5225445 Skidmore et al. Jul 1993 A
5231996 Bardy et al. Aug 1993 A
5232444 Just et al. Aug 1993 A
5234456 Silvestrini Aug 1993 A
5239982 Trauthen Aug 1993 A
5254088 Lundquist et al. Oct 1993 A
5255678 Deslauriers et al. Oct 1993 A
5255679 Imran Oct 1993 A
5265604 Vince Nov 1993 A
5269758 Taheri Dec 1993 A
5281218 Imran Jan 1994 A
5286254 Shapland et al. Feb 1994 A
5292331 Boneau Mar 1994 A
5293869 Edwards et al. Mar 1994 A
5309910 Edwards et al. May 1994 A
5311866 Kagan et al. May 1994 A
5313943 Houser et al. May 1994 A
5324255 Passafaro et al. Jun 1994 A
5324284 Imran Jun 1994 A
5343936 Beatenbough et al. Sep 1994 A
5344398 Hara Sep 1994 A
5345936 Pomeranz et al. Sep 1994 A
5348554 Imran et al. Sep 1994 A
5366443 Eggers et al. Nov 1994 A
5368591 Lennox et al. Nov 1994 A
5370644 Langberg Dec 1994 A
5370675 Edwards et al. Dec 1994 A
5370679 Atlee, III Dec 1994 A
5372603 Acker et al. Dec 1994 A
5374287 Rubin Dec 1994 A
5379765 Kajiwara et al. Jan 1995 A
5383917 Desai et al. Jan 1995 A
5393207 Maher et al. Feb 1995 A
5394880 Atlee, III Mar 1995 A
5396887 Imran Mar 1995 A
5400778 Jonson et al. Mar 1995 A
5400783 Pomeranz et al. Mar 1995 A
5405362 Kramer et al. Apr 1995 A
5405366 Fox et al. Apr 1995 A
5411025 Webster, Jr. May 1995 A
5415166 Imran May 1995 A
5415656 Tihon et al. May 1995 A
5417687 Nardella et al. May 1995 A
5422362 Vincent et al. Jun 1995 A
5423744 Gencheff et al. Jun 1995 A
5423811 Imran et al. Jun 1995 A
5425023 Haraguchi et al. Jun 1995 A
5425703 Feiring Jun 1995 A
5425811 Mashita Jun 1995 A
5431696 Atlee, III Jul 1995 A
5433730 Alt Jul 1995 A
5437665 Munro Aug 1995 A
5443470 Stern et al. Aug 1995 A
5454782 Perkins Oct 1995 A
5454840 Krakovsky et al. Oct 1995 A
5456667 Ham et al. Oct 1995 A
5458596 Lax et al. Oct 1995 A
5465717 Imran et al. Nov 1995 A
5470352 Rappaport Nov 1995 A
5471982 Edwards et al. Dec 1995 A
5474530 Passafaro et al. Dec 1995 A
5478309 Sweezer et al. Dec 1995 A
5478578 Arnold et al. Dec 1995 A
5496271 Burton et al. Mar 1996 A
5496304 Chasan Mar 1996 A
5496311 Abele et al. Mar 1996 A
5496312 Klicek Mar 1996 A
5500011 Desai Mar 1996 A
5505728 Ellman et al. Apr 1996 A
5505730 Edwards Apr 1996 A
5507791 Sitko Apr 1996 A
5509419 Edwards et al. Apr 1996 A
5522862 Testerman et al. Jun 1996 A
5531779 Dahl et al. Jul 1996 A
5540681 Strul et al. Jul 1996 A
5540730 Terry, Jr. et al. Jul 1996 A
5545161 Imran Aug 1996 A
5545193 Fleischman et al. Aug 1996 A
5547469 Rowland et al. Aug 1996 A
5549559 Eshel Aug 1996 A
5549655 Erickson Aug 1996 A
5549661 Kordis et al. Aug 1996 A
RE35330 Malone et al. Sep 1996 E
5553611 Budd et al. Sep 1996 A
5558073 Pomeranz et al. Sep 1996 A
5562608 Sekins et al. Oct 1996 A
5571074 Buckman, Jr. et al. Nov 1996 A
5571088 Lennox et al. Nov 1996 A
5574059 Regunathan et al. Nov 1996 A
5578072 Barone et al. Nov 1996 A
5582609 Swanson et al. Dec 1996 A
5588432 Crowley Dec 1996 A
5588812 Taylor et al. Dec 1996 A
5595183 Swanson et al. Jan 1997 A
5598848 Swanson et al. Feb 1997 A
5599345 Edwards et al. Feb 1997 A
5601088 Swanson et al. Feb 1997 A
5605157 Panescu et al. Feb 1997 A
5607419 Amplatz et al. Mar 1997 A
5607462 Imran Mar 1997 A
5620438 Amplatz et al. Apr 1997 A
5620463 Drolet Apr 1997 A
5623940 Daikuzono Apr 1997 A
5624392 Saab Apr 1997 A
5624439 Edwards et al. Apr 1997 A
5626618 Ward et al. May 1997 A
5630425 Panescu et al. May 1997 A
5630794 Lax et al. May 1997 A
5630813 Kieturakis May 1997 A
5634471 Fairfax et al. Jun 1997 A
5641326 Adams Jun 1997 A
5647870 Kordis et al. Jul 1997 A
5658278 Imran et al. Aug 1997 A
5658322 Fleming Aug 1997 A
5658549 Akehurst et al. Aug 1997 A
5660175 Dayal Aug 1997 A
5662108 Budd et al. Sep 1997 A
5669930 Igarashi Sep 1997 A
5669932 Fischell et al. Sep 1997 A
5674472 Akehurst et al. Oct 1997 A
5678535 DiMarco Oct 1997 A
5680860 Imran Oct 1997 A
5681280 Rusk et al. Oct 1997 A
5681308 Edwards et al. Oct 1997 A
5687723 Avitall Nov 1997 A
5688267 Panescu et al. Nov 1997 A
5690692 Fleming Nov 1997 A
5693078 Desai et al. Dec 1997 A
5694934 Edelman Dec 1997 A
5695471 Wampler Dec 1997 A
5699799 Xu et al. Dec 1997 A
5702386 Stern et al. Dec 1997 A
5707218 Maher et al. Jan 1998 A
5707336 Rubin Jan 1998 A
5707352 Sekins et al. Jan 1998 A
5707400 Terry, Jr. et al. Jan 1998 A
5722401 Pietroski et al. Mar 1998 A
5722403 McGee et al. Mar 1998 A
5722416 Swanson et al. Mar 1998 A
5725525 Kordis Mar 1998 A
5727569 Benetti et al. Mar 1998 A
5728094 Edwards Mar 1998 A
5730128 Pomeranz et al. Mar 1998 A
5730704 Avitall Mar 1998 A
5730726 Klingenstein Mar 1998 A
5730741 Horzewski et al. Mar 1998 A
5733319 Neilson et al. Mar 1998 A
5735846 Panescu et al. Apr 1998 A
5740808 Panescu et al. Apr 1998 A
5741248 Stern et al. Apr 1998 A
5746224 Edwards May 1998 A
5752518 McGee et al. May 1998 A
5755714 Murphy-Chutorian May 1998 A
5755753 Knowlton May 1998 A
5759158 Swanson Jun 1998 A
5765568 Sweezer, Jr. et al. Jun 1998 A
5766605 Sanders et al. Jun 1998 A
5769846 Edwards et al. Jun 1998 A
5772590 Webster, Jr. Jun 1998 A
5779669 Haissaguerre et al. Jul 1998 A
5779698 Clayman et al. Jul 1998 A
5782239 Webster, Jr. Jul 1998 A
5782797 Schweich, Jr. et al. Jul 1998 A
5782827 Gough et al. Jul 1998 A
5782848 Lennox Jul 1998 A
5782899 Imran Jul 1998 A
5792064 Panescu et al. Aug 1998 A
5795303 Swanson et al. Aug 1998 A
5800375 Sweezer et al. Sep 1998 A
5800486 Thome et al. Sep 1998 A
5807306 Shapland et al. Sep 1998 A
5810757 Sweezer, Jr. et al. Sep 1998 A
5810807 Ganz et al. Sep 1998 A
5814078 Zhou et al. Sep 1998 A
5817028 Anderson Oct 1998 A
5817073 Krespi Oct 1998 A
5820554 Davis et al. Oct 1998 A
5820589 Torgerson et al. Oct 1998 A
5823189 Kordis Oct 1998 A
5827277 Edwards Oct 1998 A
5833651 Donovan et al. Nov 1998 A
5836874 Swanson et al. Nov 1998 A
5836905 Lemelson et al. Nov 1998 A
5836947 Fleischman et al. Nov 1998 A
5837001 Mackey Nov 1998 A
5843075 Taylor Dec 1998 A
5843077 Edwards Dec 1998 A
5843088 Barra et al. Dec 1998 A
5846238 Jackson et al. Dec 1998 A
5848969 Panescu et al. Dec 1998 A
5848972 Triedman et al. Dec 1998 A
5849026 Zhou et al. Dec 1998 A
5855577 Murphy-Chutorian et al. Jan 1999 A
5860974 Abele Jan 1999 A
5863291 Schaer Jan 1999 A
5865791 Whayne et al. Feb 1999 A
5868740 LeVeen et al. Feb 1999 A
5871443 Edwards et al. Feb 1999 A
5871483 Jackson et al. Feb 1999 A
5871523 Fleischman et al. Feb 1999 A
5873852 Vigil et al. Feb 1999 A
5873865 Horzewski et al. Feb 1999 A
5876340 Tu et al. Mar 1999 A
5876399 Chia et al. Mar 1999 A
5881727 Edwards Mar 1999 A
5882346 Pomeranz et al. Mar 1999 A
5891027 Tu et al. Apr 1999 A
5891135 Jackson et al. Apr 1999 A
5891136 McGee et al. Apr 1999 A
5891138 Tu et al. Apr 1999 A
5891182 Fleming Apr 1999 A
5893847 Kordis Apr 1999 A
5893887 Jayaraman Apr 1999 A
5897554 Chia et al. Apr 1999 A
5899882 Waksman et al. May 1999 A
5902268 Saab May 1999 A
5904651 Swanson et al. May 1999 A
5904711 Flom et al. May 1999 A
5906636 Casscells, III et al. May 1999 A
5908445 Whayne et al. Jun 1999 A
5908446 Imran Jun 1999 A
5908839 Levitt et al. Jun 1999 A
5911218 DiMarco Jun 1999 A
5916235 Guglielmi Jun 1999 A
5919147 Jain Jul 1999 A
5919172 Golba, Jr. Jul 1999 A
5924424 Stevens et al. Jul 1999 A
5928228 Kordis et al. Jul 1999 A
5931806 Shimada Aug 1999 A
5931835 Mackey Aug 1999 A
5935079 Swanson et al. Aug 1999 A
5941869 Patterson et al. Aug 1999 A
5951494 Wang et al. Sep 1999 A
5951546 Lorentzen Sep 1999 A
5954661 Greenspon et al. Sep 1999 A
5954662 Swanson et al. Sep 1999 A
5954717 Behl et al. Sep 1999 A
5956501 Brown Sep 1999 A
5957919 Laufer Sep 1999 A
5957961 Maguire et al. Sep 1999 A
5964223 Baran Oct 1999 A
5964753 Edwards Oct 1999 A
5964796 Imran Oct 1999 A
5971983 Lesh Oct 1999 A
5972026 Laufer et al. Oct 1999 A
5976175 Hirano et al. Nov 1999 A
5976709 Kageyama et al. Nov 1999 A
5979456 Magovern Nov 1999 A
5980563 Tu et al. Nov 1999 A
5984917 Fleischman et al. Nov 1999 A
5984971 Faccioli et al. Nov 1999 A
5989545 Foster et al. Nov 1999 A
5991650 Swanson et al. Nov 1999 A
5992419 Sterzer et al. Nov 1999 A
5993462 Pomeranz et al. Nov 1999 A
5995873 Rhodes Nov 1999 A
5997534 Tu et al. Dec 1999 A
5999855 DiMarco Dec 1999 A
6001054 Regulla et al. Dec 1999 A
6003517 Sheffield et al. Dec 1999 A
6004269 Crowley et al. Dec 1999 A
6006134 Hill et al. Dec 1999 A
6006755 Edwards Dec 1999 A
6008211 Robinson et al. Dec 1999 A
6009877 Edwards Jan 2000 A
6010500 Sherman et al. Jan 2000 A
6014579 Pomeranz et al. Jan 2000 A
6016437 Tu et al. Jan 2000 A
6023638 Swanson Feb 2000 A
6024740 Lesh et al. Feb 2000 A
6029091 De La Rama et al. Feb 2000 A
6033397 Laufer et al. Mar 2000 A
6036687 Laufer et al. Mar 2000 A
6036689 Tu et al. Mar 2000 A
6039731 Taylor et al. Mar 2000 A
6043273 Duhaylongsod Mar 2000 A
6045549 Smethers et al. Apr 2000 A
6045550 Simpson et al. Apr 2000 A
6050992 Nichols Apr 2000 A
6052607 Edwards et al. Apr 2000 A
6053172 Hovda et al. Apr 2000 A
6053909 Shadduck Apr 2000 A
6056744 Edwards May 2000 A
6056745 Panescu et al. May 2000 A
6056769 Epstein et al. May 2000 A
6060454 Duhaylongsod May 2000 A
6063078 Wittkampf May 2000 A
6063768 First May 2000 A
6071280 Edwards et al. Jun 2000 A
6071281 Burnside et al. Jun 2000 A
6071282 Fleischman Jun 2000 A
6081749 Ingle et al. Jun 2000 A
6083249 Familoni Jul 2000 A
6083255 Laufer et al. Jul 2000 A
6087394 Duhaylongsod Jul 2000 A
6090104 Webster, Jr. Jul 2000 A
6091995 Ingle et al. Jul 2000 A
6092528 Edwards Jul 2000 A
6097985 Kasevich et al. Aug 2000 A
6101412 Duhaylongsod Aug 2000 A
6102886 Lundquist et al. Aug 2000 A
6106524 Eggers et al. Aug 2000 A
6117101 Diederich et al. Sep 2000 A
6123702 Swanson et al. Sep 2000 A
6123703 Tu et al. Sep 2000 A
6123718 Tu et al. Sep 2000 A
6125301 Capel Sep 2000 A
6127410 Duhaylongsod Oct 2000 A
6129726 Edwards et al. Oct 2000 A
6135997 Laufer et al. Oct 2000 A
6139527 Laufer et al. Oct 2000 A
6139571 Fuller et al. Oct 2000 A
6139845 Donovan Oct 2000 A
6141589 Duhaylongsod Oct 2000 A
6142993 Whayne et al. Nov 2000 A
6143013 Samson et al. Nov 2000 A
6143277 Ashurst et al. Nov 2000 A
6149647 Tu et al. Nov 2000 A
6152143 Edwards Nov 2000 A
6152899 Farley et al. Nov 2000 A
6152953 Hipskind Nov 2000 A
6159194 Eggers et al. Dec 2000 A
6163716 Edwards et al. Dec 2000 A
6174323 Biggs et al. Jan 2001 B1
6179833 Taylor Jan 2001 B1
6183468 Swanson et al. Feb 2001 B1
6197013 Reed et al. Mar 2001 B1
6198970 Freed et al. Mar 2001 B1
6200311 Danek et al. Mar 2001 B1
6200332 Del Giglio Mar 2001 B1
6200333 Laufer Mar 2001 B1
6203562 Ohkubo Mar 2001 B1
6210367 Carr Apr 2001 B1
6212432 Matsuura Apr 2001 B1
6212433 Behl Apr 2001 B1
6214002 Fleischman et al. Apr 2001 B1
6216043 Swanson et al. Apr 2001 B1
6216044 Kordis Apr 2001 B1
6216704 Ingle et al. Apr 2001 B1
6217576 Tu et al. Apr 2001 B1
6226543 Gilboa et al. May 2001 B1
6230052 Wolff et al. May 2001 B1
6231595 Dobak, III May 2001 B1
6235024 Tu May 2001 B1
6240307 Beatty et al. May 2001 B1
6241727 Tu et al. Jun 2001 B1
6245065 Panescu et al. Jun 2001 B1
6251368 Akehurst et al. Jun 2001 B1
6253762 Britto Jul 2001 B1
6254598 Edwards et al. Jul 2001 B1
6254599 Lesh et al. Jul 2001 B1
6258083 Daniel et al. Jul 2001 B1
6258087 Edwards et al. Jul 2001 B1
6264653 Falwell Jul 2001 B1
6265379 Donovan Jul 2001 B1
6269813 Fitzgerald et al. Aug 2001 B1
6270476 Santoianni et al. Aug 2001 B1
6273886 Edwards et al. Aug 2001 B1
6273907 Laufer Aug 2001 B1
6283987 Laird et al. Sep 2001 B1
6283988 Laufer et al. Sep 2001 B1
6283989 Laufer et al. Sep 2001 B1
6287304 Eggers et al. Sep 2001 B1
6296639 Truckai et al. Oct 2001 B1
6299633 Laufer Oct 2001 B1
6302870 Jacobsen et al. Oct 2001 B1
6303509 Chen et al. Oct 2001 B1
6306423 Donovan et al. Oct 2001 B1
6315173 Di Giovanni et al. Nov 2001 B1
6315778 Gambale et al. Nov 2001 B1
6317615 KenKnight et al. Nov 2001 B1
6322559 Daulton et al. Nov 2001 B1
6322584 Ingle et al. Nov 2001 B2
6325798 Edwards et al. Dec 2001 B1
6327503 Familoni Dec 2001 B1
6338727 Noda et al. Jan 2002 B1
6338836 Kuth et al. Jan 2002 B1
6341236 Osorio et al. Jan 2002 B1
6346104 Daly et al. Feb 2002 B2
6355031 Edwards et al. Mar 2002 B1
6356786 Rezai et al. Mar 2002 B1
6356787 Rezai et al. Mar 2002 B1
6357447 Swanson et al. Mar 2002 B1
6358245 Edwards et al. Mar 2002 B1
6358926 Donovan Mar 2002 B2
6361554 Brisken Mar 2002 B1
6363937 Hovda et al. Apr 2002 B1
6366814 Boveja et al. Apr 2002 B1
6379352 Reynolds et al. Apr 2002 B1
6383509 Donovan et al. May 2002 B1
6394956 Chandrasekaran et al. May 2002 B1
6402744 Edwards et al. Jun 2002 B2
6405732 Edwards et al. Jun 2002 B1
6409723 Edwards Jun 2002 B1
6411852 Danek et al. Jun 2002 B1
6414018 Duhaylongsod Jul 2002 B1
6416511 Lesh et al. Jul 2002 B1
6416740 Unger Jul 2002 B1
6423058 Edwards et al. Jul 2002 B1
6423105 Iijima et al. Jul 2002 B1
6424864 Matsuura Jul 2002 B1
6425877 Edwards Jul 2002 B1
6425887 McGuckin et al. Jul 2002 B1
6425895 Swanson et al. Jul 2002 B1
6432092 Miller Aug 2002 B2
6436130 Philips et al. Aug 2002 B1
6438423 Rezai et al. Aug 2002 B1
6440128 Edwards et al. Aug 2002 B1
6440129 Simpson Aug 2002 B1
6442435 King et al. Aug 2002 B2
6447505 McGovern et al. Sep 2002 B2
6447785 Donovan Sep 2002 B1
6448231 Graham Sep 2002 B2
6458121 Rosenstock et al. Oct 2002 B1
6460545 Kordis Oct 2002 B2
6464680 Brisken et al. Oct 2002 B1
6464697 Edwards et al. Oct 2002 B1
6475160 Sher Nov 2002 B1
6480746 Ingle et al. Nov 2002 B1
6485416 Platt et al. Nov 2002 B1
6488673 Laufer et al. Dec 2002 B1
6488679 Swanson et al. Dec 2002 B1
6491710 Satake Dec 2002 B2
6493589 Medhkour et al. Dec 2002 B1
6494880 Swanson et al. Dec 2002 B1
6496737 Rudie et al. Dec 2002 B2
6496738 Carr Dec 2002 B2
6506399 Donovan Jan 2003 B2
6510969 Di Giovanni et al. Jan 2003 B2
6514246 Swanson et al. Feb 2003 B1
6514290 Loomas Feb 2003 B1
6519488 KenKnight et al. Feb 2003 B2
6522913 Swanson et al. Feb 2003 B2
6524555 Ashurst et al. Feb 2003 B1
6526320 Mitchell Feb 2003 B2
6526976 Baran Mar 2003 B1
6529756 Phan et al. Mar 2003 B1
6532388 Hill et al. Mar 2003 B1
6533780 Laird et al. Mar 2003 B1
6536427 Davies et al. Mar 2003 B2
6544226 Gaiser et al. Apr 2003 B1
6544262 Fleischman Apr 2003 B2
6546928 Ashurst et al. Apr 2003 B1
6546932 Nahon et al. Apr 2003 B1
6546934 Ingle et al. Apr 2003 B1
6547776 Gaiser et al. Apr 2003 B1
6547788 Maguire et al. Apr 2003 B1
6549808 Gisel et al. Apr 2003 B1
6551274 Heiner Apr 2003 B2
6551310 Ganz et al. Apr 2003 B1
6558333 Gilboa et al. May 2003 B2
6558378 Sherman et al. May 2003 B2
6558381 Ingle et al. May 2003 B2
6562034 Edwards et al. May 2003 B2
6572612 Stewart et al. Jun 2003 B2
6575623 Werneth Jun 2003 B2
6575969 Rittman, III et al. Jun 2003 B1
6582427 Goble et al. Jun 2003 B1
6582430 Hall Jun 2003 B2
6587718 Talpade Jul 2003 B2
6587719 Barrett et al. Jul 2003 B1
6587731 Ingle et al. Jul 2003 B1
6589235 Wong et al. Jul 2003 B2
6589238 Edwards et al. Jul 2003 B2
6593130 Sen et al. Jul 2003 B1
6599311 Biggs et al. Jul 2003 B1
6601581 Babaev Aug 2003 B1
6603996 Beatty et al. Aug 2003 B1
6610054 Edwards et al. Aug 2003 B1
6610083 Keller et al. Aug 2003 B2
6610713 Tracey Aug 2003 B2
6613002 Clark et al. Sep 2003 B1
6613045 Laufer et al. Sep 2003 B1
6620159 Hegde Sep 2003 B2
6620415 Donovan Sep 2003 B2
6622047 Barrett et al. Sep 2003 B2
6623742 Voet Sep 2003 B2
6626855 Weng et al. Sep 2003 B1
6626903 McGuckin, Jr. et al. Sep 2003 B2
6629535 Ingle et al. Oct 2003 B2
6629951 Laufer et al. Oct 2003 B2
6632440 Quinn et al. Oct 2003 B1
6633779 Schuler et al. Oct 2003 B1
6634363 Danek et al. Oct 2003 B1
6635054 Fjield et al. Oct 2003 B2
6635056 Kadhiresan et al. Oct 2003 B2
6638273 Farley et al. Oct 2003 B1
6640119 Budd et al. Oct 2003 B1
6640120 Swanson et al. Oct 2003 B1
6645200 Koblish et al. Nov 2003 B1
6645496 Aoki et al. Nov 2003 B2
6647617 Beatty et al. Nov 2003 B1
6648881 KenKnight et al. Nov 2003 B2
6649161 Donovan Nov 2003 B1
6652517 Hall et al. Nov 2003 B1
6652548 Evans et al. Nov 2003 B2
6656960 Puskas Dec 2003 B2
6658279 Swanson et al. Dec 2003 B2
6663622 Foley et al. Dec 2003 B1
6666858 Lafontaine Dec 2003 B2
6669693 Friedman Dec 2003 B2
6673068 Berube Jan 2004 B1
6673070 Edwards et al. Jan 2004 B2
6675047 Konoplev et al. Jan 2004 B1
6676686 Naganuma Jan 2004 B2
6681136 Schuler et al. Jan 2004 B2
6692492 Simpson et al. Feb 2004 B2
6692494 Cooper et al. Feb 2004 B1
6699180 Kobayashi Mar 2004 B2
6699243 West et al. Mar 2004 B2
6708064 Rezai Mar 2004 B2
6711436 Duhaylongsod Mar 2004 B1
6712074 Edwards et al. Mar 2004 B2
6712812 Roschak et al. Mar 2004 B2
6712814 Edwards et al. Mar 2004 B2
6714822 King et al. Mar 2004 B2
6719685 Fujikura et al. Apr 2004 B2
6719694 Weng et al. Apr 2004 B2
6723053 Ackerman et al. Apr 2004 B2
6723091 Goble et al. Apr 2004 B2
6728562 Budd et al. Apr 2004 B1
6735471 Hill et al. May 2004 B2
6735475 Whitehurst et al. May 2004 B1
6740321 Donovan May 2004 B1
6743197 Edwards Jun 2004 B1
6743413 Schultz et al. Jun 2004 B1
6749604 Eggers et al. Jun 2004 B1
6749606 Keast et al. Jun 2004 B2
6752765 Jensen et al. Jun 2004 B1
6755026 Wallach Jun 2004 B2
6755849 Gowda et al. Jun 2004 B1
6767347 Sharkey et al. Jul 2004 B2
6767544 Brooks et al. Jul 2004 B2
6770070 Balbierz Aug 2004 B1
6772013 Ingle et al. Aug 2004 B1
6773711 Voet et al. Aug 2004 B2
6776991 Naumann Aug 2004 B2
6777423 Banholzer et al. Aug 2004 B2
6778854 Puskas Aug 2004 B2
6780183 Jimenez et al. Aug 2004 B2
6786889 Musbach et al. Sep 2004 B1
6802843 Truckai et al. Oct 2004 B2
6805131 Kordis Oct 2004 B2
6819956 DiLorenzo Nov 2004 B2
6826420 Beatty et al. Nov 2004 B1
6826421 Beatty et al. Nov 2004 B1
6827931 Donovan Dec 2004 B1
6836688 Ingle et al. Dec 2004 B2
6837888 Ciarrocca et al. Jan 2005 B2
6838429 Paslin Jan 2005 B2
6838434 Voet Jan 2005 B2
6838471 Tracey Jan 2005 B2
6840243 Deem et al. Jan 2005 B2
6841156 Aoki et al. Jan 2005 B2
6843998 Steward et al. Jan 2005 B1
6846312 Edwards et al. Jan 2005 B2
6847849 Mamo et al. Jan 2005 B2
6849073 Hoey et al. Feb 2005 B2
6852091 Edwards et al. Feb 2005 B2
6852110 Roy et al. Feb 2005 B2
6861058 Aoki et al. Mar 2005 B2
6866662 Fuimaono et al. Mar 2005 B2
6871092 Piccone Mar 2005 B2
6872206 Edwards et al. Mar 2005 B2
6872397 Aoki et al. Mar 2005 B2
6878156 Noda Apr 2005 B1
6881213 Ryan et al. Apr 2005 B2
6885888 Rezai Apr 2005 B2
6890347 Machold et al. May 2005 B2
6893436 Woodard et al. May 2005 B2
6893438 Hall et al. May 2005 B2
6893439 Fleischman May 2005 B2
6895267 Panescu et al. May 2005 B2
6904303 Phan et al. Jun 2005 B2
6908462 Joye et al. Jun 2005 B2
6908928 Banholzer et al. Jun 2005 B2
6913616 Hamilton et al. Jul 2005 B2
6917834 Koblish et al. Jul 2005 B2
6934583 Weinberg et al. Aug 2005 B2
6937896 Kroll Aug 2005 B1
6937903 Schuler et al. Aug 2005 B2
6939309 Beatty et al. Sep 2005 B1
6939345 KenKnight et al. Sep 2005 B2
6939346 Kannenberg et al. Sep 2005 B2
6947785 Beatty et al. Sep 2005 B1
6954977 Maguire et al. Oct 2005 B2
6957106 Schuler et al. Oct 2005 B2
6961622 Gilbert Nov 2005 B2
6970742 Mann et al. Nov 2005 B2
RE38912 Walz et al. Dec 2005 E
6971395 Edwards et al. Dec 2005 B2
6974224 Thomas-Benedict Dec 2005 B2
6974456 Edwards et al. Dec 2005 B2
6974578 Aoki et al. Dec 2005 B1
6978168 Beatty et al. Dec 2005 B2
6978174 Gelfand et al. Dec 2005 B2
6990370 Beatty et al. Jan 2006 B1
6994706 Chomenky et al. Feb 2006 B2
6997189 Biggs et al. Feb 2006 B2
7004942 Laird et al. Feb 2006 B2
7022088 Keast et al. Apr 2006 B2
7022105 Edwards Apr 2006 B1
7027869 Danek et al. Apr 2006 B2
7043307 Zelickson et al. May 2006 B1
7070800 Bechtold-Peters et al. Jul 2006 B2
7072720 Puskas Jul 2006 B2
7083614 Fjield et al. Aug 2006 B2
7101368 Lafontaine Sep 2006 B2
7101387 Garabedian et al. Sep 2006 B2
7104987 Biggs et al. Sep 2006 B2
7104990 Jenkins et al. Sep 2006 B2
7112198 Satake Sep 2006 B2
7118568 Hassett et al. Oct 2006 B2
7122031 Edwards et al. Oct 2006 B2
7122033 Wood Oct 2006 B2
7125407 Edwards et al. Oct 2006 B2
7131445 Amoah Nov 2006 B2
7142910 Puskas Nov 2006 B2
7150745 Stem et al. Dec 2006 B2
7162303 Levin et al. Jan 2007 B2
7165551 Edwards et al. Jan 2007 B2
7167757 Ingle et al. Jan 2007 B2
7175644 Cooper et al. Feb 2007 B2
7179257 West et al. Feb 2007 B2
7186251 Malecki et al. Mar 2007 B2
7187964 Khoury Mar 2007 B2
7187973 Hauck Mar 2007 B2
7189208 Beatty et al. Mar 2007 B1
7198635 Danek et al. Apr 2007 B2
7200445 Dalbec et al. Apr 2007 B1
7229469 Witzel et al. Jun 2007 B1
7238357 Barron Jul 2007 B2
7241295 Maguire Jul 2007 B2
7255693 Johnston et al. Aug 2007 B1
RE39820 Banholzer et al. Sep 2007 E
7264002 Danek et al. Sep 2007 B2
7266414 Cornelius et al. Sep 2007 B2
7273055 Danek et al. Sep 2007 B2
7289843 Beatty et al. Oct 2007 B2
7291146 Steinke et al. Nov 2007 B2
7292890 Whitehurst et al. Nov 2007 B2
7309707 Bender et al. Dec 2007 B2
7310552 Puskas Dec 2007 B2
RE40045 Palmer Feb 2008 E
7326207 Edwards Feb 2008 B2
7344535 Stem et al. Mar 2008 B2
7371231 Rioux et al. May 2008 B2
7393330 Keast et al. Jul 2008 B2
7393350 Maurice Jul 2008 B2
7394976 Entenman et al. Jul 2008 B2
7402172 Chin et al. Jul 2008 B2
7422563 Roschak et al. Sep 2008 B2
7422584 Loomas et al. Sep 2008 B2
7425212 Danek et al. Sep 2008 B1
7430449 Aldrich et al. Sep 2008 B2
7462162 Phan et al. Dec 2008 B2
7462179 Edwards et al. Dec 2008 B2
7473273 Campbell Jan 2009 B2
7477945 Rezai et al. Jan 2009 B2
7483755 Ingle et al. Jan 2009 B2
7493160 Weber et al. Feb 2009 B2
7494661 Sanders Feb 2009 B2
7507234 Utley et al. Mar 2009 B2
7507238 Edwards et al. Mar 2009 B2
7517320 Wibowo et al. Apr 2009 B2
7530979 Ganz et al. May 2009 B2
7532938 Machado et al. May 2009 B2
7542802 Danek et al. Jun 2009 B2
7553307 Bleich et al. Jun 2009 B2
7556624 Laufer et al. Jul 2009 B2
7559890 Wallace et al. Jul 2009 B2
7572245 Herweck et al. Aug 2009 B2
7585296 Edwards et al. Sep 2009 B2
7588549 Eccleston Sep 2009 B2
7594925 Danek et al. Sep 2009 B2
7608275 Deem et al. Oct 2009 B2
7613515 Knudson et al. Nov 2009 B2
7617005 Demarais et al. Nov 2009 B2
7620451 Demarais et al. Nov 2009 B2
7628789 Soltesz et al. Dec 2009 B2
7632268 Edwards et al. Dec 2009 B2
7641632 Noda et al. Jan 2010 B2
7641633 Laufer et al. Jan 2010 B2
7648500 Edwards et al. Jan 2010 B2
7653438 Deem et al. Jan 2010 B2
7684865 Aldrich et al. Mar 2010 B2
7689290 Ingle et al. Mar 2010 B2
7691079 Gobel Apr 2010 B2
RE41334 Beatty et al. May 2010 E
7708712 Phan et al. May 2010 B2
7708768 Danek et al. May 2010 B2
7711430 Errico et al. May 2010 B2
7717948 Demarais et al. May 2010 B2
7722538 Khoury May 2010 B2
7725188 Errico et al. May 2010 B2
7734355 Cohen et al. Jun 2010 B2
7734535 Bums Jun 2010 B1
7740017 Danek et al. Jun 2010 B2
7740631 Bleich et al. Jun 2010 B2
7742795 Stone et al. Jun 2010 B2
7747324 Errico et al. Jun 2010 B2
7756583 Demarais et al. Jul 2010 B2
7765010 Chomenky et al. Jul 2010 B2
7770584 Danek et al. Aug 2010 B2
7783358 Aldrich et al. Aug 2010 B2
7815590 Cooper Oct 2010 B2
7826881 Beatty et al. Nov 2010 B1
7831288 Beatty et al. Nov 2010 B1
7837676 Sinelnikov et al. Nov 2010 B2
7837679 Biggs et al. Nov 2010 B2
7841986 He et al. Nov 2010 B2
7844338 Knudson et al. Nov 2010 B2
7853331 Kaplan et al. Dec 2010 B2
7854734 Biggs et al. Dec 2010 B2
7854740 Carney Dec 2010 B2
7869879 Errico et al. Jan 2011 B2
7869880 Errico et al. Jan 2011 B2
7873417 Demarais et al. Jan 2011 B2
7877146 Rezai et al. Jan 2011 B2
7904159 Errico et al. Mar 2011 B2
7906124 Laufer et al. Mar 2011 B2
7914448 Bob et al. Mar 2011 B2
7921855 Danek et al. Apr 2011 B2
7930012 Beatty et al. Apr 2011 B2
7931647 Wizeman et al. Apr 2011 B2
7937143 Demarais et al. May 2011 B2
7938123 Danek et al. May 2011 B2
7949407 Kaplan et al. May 2011 B2
7967782 Laufer et al. Jun 2011 B2
7985187 Wibowo et al. Jul 2011 B2
7992572 Danek et al. Aug 2011 B2
7993336 Jackson et al. Aug 2011 B2
8002740 Willink et al. Aug 2011 B2
8010197 Errico et al. Aug 2011 B2
8012149 Jackson et al. Sep 2011 B2
8041428 Errico et al. Oct 2011 B2
8046085 Knudson et al. Oct 2011 B2
8052668 Sih Nov 2011 B2
8088127 Mayse et al. Jan 2012 B2
8099167 Errico et al. Jan 2012 B1
8105817 Deem et al. Jan 2012 B2
8128595 Walker et al. Mar 2012 B2
8128617 Bencini et al. Mar 2012 B2
8131371 Demarals et al. Mar 2012 B2
8133497 Deem et al. Mar 2012 B2
8152803 Edwards et al. Apr 2012 B2
8172827 Deem et al. May 2012 B2
8204598 Errico et al. Jun 2012 B2
8208998 Beatty et al. Jun 2012 B2
8209034 Simon et al. Jun 2012 B2
8216216 Warnking et al. Jul 2012 B2
8226638 Mayse et al. Jul 2012 B2
8229564 Rezai Jul 2012 B2
8231621 Hutchins et al. Jul 2012 B2
8233988 Errico et al. Jul 2012 B2
8251992 Utley et al. Aug 2012 B2
8267094 Danek et al. Sep 2012 B2
8295902 Salahieh et al. Oct 2012 B2
8303581 Arts et al. Nov 2012 B2
8313484 Edwards et al. Nov 2012 B2
8328798 Witzel et al. Dec 2012 B2
8338164 Deem et al. Dec 2012 B2
8347891 Demarais et al. Jan 2013 B2
8357118 Orr Jan 2013 B2
8364237 Stone et al. Jan 2013 B2
8371303 Schaner et al. Feb 2013 B2
8377055 Jackson et al. Feb 2013 B2
8483831 Hlavka et al. Jul 2013 B1
8489192 Hlavka et al. Jul 2013 B1
8731672 Hlavka et al. May 2014 B2
8740895 Mayse et al. Jun 2014 B2
8777943 Mayse et al. Jul 2014 B2
8808280 Mayse et al. Aug 2014 B2
8821489 Mayse et al. Sep 2014 B2
8911439 Mayse et al. Dec 2014 B2
8932289 Mayse et al. Jan 2015 B2
8961507 Mayse et al. Feb 2015 B2
8961508 Mayse et al. Feb 2015 B2
9005195 Mayse et al. Apr 2015 B2
9017324 Mayse et al. Apr 2015 B2
20010020151 Reed et al. Sep 2001 A1
20010044596 Jaafar Nov 2001 A1
20020002387 Naganuma Jan 2002 A1
20020010495 Freed et al. Jan 2002 A1
20020016344 Tracey Feb 2002 A1
20020042564 Cooper et al. Apr 2002 A1
20020042565 Cooper et al. Apr 2002 A1
20020049370 Laufer et al. Apr 2002 A1
20020072738 Edwards et al. Jun 2002 A1
20020082197 Aoki et al. Jun 2002 A1
20020087153 Roschak et al. Jul 2002 A1
20020087208 Koblish et al. Jul 2002 A1
20020091379 Danek et al. Jul 2002 A1
20020107512 Edwards Aug 2002 A1
20020107515 Edwards et al. Aug 2002 A1
20020111386 Sekins et al. Aug 2002 A1
20020111619 Keast et al. Aug 2002 A1
20020111620 Cooper et al. Aug 2002 A1
20020115991 Edwards Aug 2002 A1
20020116030 Rezai Aug 2002 A1
20020143302 Hinchliffe et al. Oct 2002 A1
20020143326 Foley et al. Oct 2002 A1
20020143373 Courtnage et al. Oct 2002 A1
20020151888 Edwards et al. Oct 2002 A1
20020183682 Darvish et al. Dec 2002 A1
20020198512 Seward Dec 2002 A1
20020198570 Puskas Dec 2002 A1
20020198574 Gumpert Dec 2002 A1
20030018327 Truckai et al. Jan 2003 A1
20030018344 Kaji et al. Jan 2003 A1
20030023287 Edwards et al. Jan 2003 A1
20030027752 Steward et al. Feb 2003 A1
20030050591 Patrick McHale Mar 2003 A1
20030050631 Mody et al. Mar 2003 A1
20030065371 Satake Apr 2003 A1
20030069570 Witzel et al. Apr 2003 A1
20030070676 Cooper et al. Apr 2003 A1
20030074039 Puskas Apr 2003 A1
20030093069 Panescu et al. May 2003 A1
20030093128 Freed et al. May 2003 A1
20030125786 Gliner et al. Jul 2003 A1
20030130571 Lattouf Jul 2003 A1
20030130657 Tom et al. Jul 2003 A1
20030144572 Oschman et al. Jul 2003 A1
20030153905 Edwards et al. Aug 2003 A1
20030159700 Laufer et al. Aug 2003 A1
20030181949 Whale Sep 2003 A1
20030187430 Vorisek Oct 2003 A1
20030195593 Ingle et al. Oct 2003 A1
20030195604 Ingle et al. Oct 2003 A1
20030202990 Donovan et al. Oct 2003 A1
20030208103 Sonnenschein et al. Nov 2003 A1
20030211121 Donovan Nov 2003 A1
20030216791 Schuler et al. Nov 2003 A1
20030216792 Levin et al. Nov 2003 A1
20030216891 Wegener Nov 2003 A1
20030225443 Kiran et al. Dec 2003 A1
20030233099 Danaek et al. Dec 2003 A1
20030236455 Swanson et al. Dec 2003 A1
20040006268 Gilboa et al. Jan 2004 A1
20040009180 Donovan Jan 2004 A1
20040010289 Biggs et al. Jan 2004 A1
20040010290 Schroeppel et al. Jan 2004 A1
20040028676 Klein et al. Feb 2004 A1
20040029849 Schatzberg et al. Feb 2004 A1
20040030368 Kemeny et al. Feb 2004 A1
20040031494 Danek et al. Feb 2004 A1
20040044390 Szeles Mar 2004 A1
20040059383 Puskas Mar 2004 A1
20040073201 Cooper et al. Apr 2004 A1
20040073206 Foley et al. Apr 2004 A1
20040073278 Pachys Apr 2004 A1
20040086531 Barron May 2004 A1
20040087936 Stem et al. May 2004 A1
20040088030 Jung, Jr. May 2004 A1
20040088036 Gilbert May 2004 A1
20040091880 Wiebusch et al. May 2004 A1
20040106954 Whitehurst et al. Jun 2004 A1
20040116981 Mazar Jun 2004 A1
20040122488 Mazar et al. Jun 2004 A1
20040122489 Mazar et al. Jun 2004 A1
20040127942 Yomtov et al. Jul 2004 A1
20040127958 Mazar et al. Jul 2004 A1
20040142005 Brooks et al. Jul 2004 A1
20040147921 Edwards et al. Jul 2004 A1
20040147969 Mann et al. Jul 2004 A1
20040147988 Stephens Jul 2004 A1
20040151741 Borodic Aug 2004 A1
20040153056 Muller et al. Aug 2004 A1
20040162584 Hill et al. Aug 2004 A1
20040162597 Hamilton et al. Aug 2004 A1
20040167509 Taimisto Aug 2004 A1
20040167580 Mann et al. Aug 2004 A1
20040172075 Shafer et al. Sep 2004 A1
20040172080 Stadler et al. Sep 2004 A1
20040172084 Knudson et al. Sep 2004 A1
20040175399 Schiffman Sep 2004 A1
20040176803 Whelan et al. Sep 2004 A1
20040176805 Whelan et al. Sep 2004 A1
20040182399 Danek et al. Sep 2004 A1
20040186435 Seward Sep 2004 A1
20040204747 Kemeny et al. Oct 2004 A1
20040213813 Ackerman Oct 2004 A1
20040213814 Ackerman Oct 2004 A1
20040215235 Jackson et al. Oct 2004 A1
20040215289 Fukui Oct 2004 A1
20040215296 Ganz et al. Oct 2004 A1
20040220556 Cooper et al. Nov 2004 A1
20040220621 Zhou et al. Nov 2004 A1
20040226556 Deem et al. Nov 2004 A1
20040230251 Schuler et al. Nov 2004 A1
20040230252 Kullok et al. Nov 2004 A1
20040243118 Ayers et al. Dec 2004 A1
20040243182 Cohen et al. Dec 2004 A1
20040248188 Sanders Dec 2004 A1
20040249401 Rabiner et al. Dec 2004 A1
20040249416 Yun et al. Dec 2004 A1
20040253274 Voet Dec 2004 A1
20050004609 Stahmann et al. Jan 2005 A1
20050004631 Benedict Jan 2005 A1
20050010263 Schauerte Jan 2005 A1
20050010270 Laufer Jan 2005 A1
20050015117 Gerber Jan 2005 A1
20050019346 Boulis Jan 2005 A1
20050021092 Yun et al. Jan 2005 A1
20050049615 Cooper et al. Mar 2005 A1
20050056292 Cooper Mar 2005 A1
20050059153 George et al. Mar 2005 A1
20050060041 Phan et al. Mar 2005 A1
20050060042 Phan et al. Mar 2005 A1
20050060044 Roschak et al. Mar 2005 A1
20050065553 Ben Ezra et al. Mar 2005 A1
20050065562 Rezai Mar 2005 A1
20050065567 Lee et al. Mar 2005 A1
20050065573 Rezai Mar 2005 A1
20050065574 Rezai Mar 2005 A1
20050065575 Dobak Mar 2005 A1
20050065584 Schiff et al. Mar 2005 A1
20050074461 Donovan Apr 2005 A1
20050076909 Stahmann et al. Apr 2005 A1
20050080461 Stahmann et al. Apr 2005 A1
20050085801 Cooper et al. Apr 2005 A1
20050090722 Perez Apr 2005 A1
20050096529 Cooper et al. May 2005 A1
20050096644 Hall et al. May 2005 A1
20050107783 Tom et al. May 2005 A1
20050107829 Edwards et al. May 2005 A1
20050107853 Krespi et al. May 2005 A1
20050125044 Tracey Jun 2005 A1
20050137518 Biggs et al. Jun 2005 A1
20050137611 Escudero et al. Jun 2005 A1
20050137715 Phan et al. Jun 2005 A1
20050143788 Yun et al. Jun 2005 A1
20050149146 Boveja et al. Jul 2005 A1
20050152924 Voet Jul 2005 A1
20050153885 Yun et al. Jul 2005 A1
20050159736 Danek et al. Jul 2005 A9
20050165456 Mann et al. Jul 2005 A1
20050171396 Pankratov et al. Aug 2005 A1
20050177144 Phan et al. Aug 2005 A1
20050177192 Rezai et al. Aug 2005 A1
20050182288 Zabara Aug 2005 A1
20050182393 Abboud et al. Aug 2005 A1
20050183732 Edwards Aug 2005 A1
20050187579 Danek et al. Aug 2005 A1
20050193279 Daners Sep 2005 A1
20050203503 Edwards et al. Sep 2005 A1
20050222628 Krakousky Oct 2005 A1
20050222635 Krakovsky Oct 2005 A1
20050222651 Jung, Jr. Oct 2005 A1
20050228054 Tatton Oct 2005 A1
20050228459 Levin et al. Oct 2005 A1
20050228460 Levin et al. Oct 2005 A1
20050234523 Levin et al. Oct 2005 A1
20050238693 Whyte Oct 2005 A1
20050240176 Oral et al. Oct 2005 A1
20050240241 Yun et al. Oct 2005 A1
20050245992 Persen et al. Nov 2005 A1
20050251128 Amoah Nov 2005 A1
20050251213 Freeman Nov 2005 A1
20050255317 Bavaro et al. Nov 2005 A1
20050256028 Yun et al. Nov 2005 A1
20050261747 Schuler et al. Nov 2005 A1
20050267536 Freeman et al. Dec 2005 A1
20050277993 Mower Dec 2005 A1
20050283197 Daum et al. Dec 2005 A1
20060015151 Aldrich Jan 2006 A1
20060058692 Beatty et al. Mar 2006 A1
20060058693 Beatty et al. Mar 2006 A1
20060058780 Edwards et al. Mar 2006 A1
20060062808 Laufer et al. Mar 2006 A1
20060079887 Buysse et al. Apr 2006 A1
20060084884 Beatty et al. Apr 2006 A1
20060084966 Maguire et al. Apr 2006 A1
20060084970 Beatty et al. Apr 2006 A1
20060084971 Beatty et al. Apr 2006 A1
20060084972 Beatty et al. Apr 2006 A1
20060089637 Werneth et al. Apr 2006 A1
20060095032 Jackson et al. May 2006 A1
20060100666 Wilkinson et al. May 2006 A1
20060106361 Muni et al. May 2006 A1
20060111755 Stone et al. May 2006 A1
20060116749 Willink et al. Jun 2006 A1
20060135953 Kania et al. Jun 2006 A1
20060135984 Kramer et al. Jun 2006 A1
20060135998 Libbus et al. Jun 2006 A1
20060137698 Danek et al. Jun 2006 A1
20060142801 Demarais et al. Jun 2006 A1
20060167498 DiLorenzo Jul 2006 A1
20060178703 Huston et al. Aug 2006 A1
20060206150 Demarais et al. Sep 2006 A1
20060212076 Demarais et al. Sep 2006 A1
20060212078 Demarais et al. Sep 2006 A1
20060222667 Deem et al. Oct 2006 A1
20060225742 Deem et al. Oct 2006 A1
20060235474 Demarais Oct 2006 A1
20060241523 Sinelnikov et al. Oct 2006 A1
20060247617 Danek et al. Nov 2006 A1
20060247618 Kaplan et al. Nov 2006 A1
20060247619 Kaplan et al. Nov 2006 A1
20060247683 Danek et al. Nov 2006 A1
20060247726 Biggs et al. Nov 2006 A1
20060247727 Biggs et al. Nov 2006 A1
20060247746 Danek et al. Nov 2006 A1
20060254600 Danek et al. Nov 2006 A1
20060259028 Utley et al. Nov 2006 A1
20060259029 Utley et al. Nov 2006 A1
20060259030 Utley et al. Nov 2006 A1
20060265014 Demarais et al. Nov 2006 A1
20060265015 Demarais et al. Nov 2006 A1
20060271111 Demarais et al. Nov 2006 A1
20060276807 Keast et al. Dec 2006 A1
20060276852 Demarais et al. Dec 2006 A1
20060278243 Danek et al. Dec 2006 A1
20060278244 Danek et al. Dec 2006 A1
20060280772 Roschak et al. Dec 2006 A1
20060280773 Roschak et al. Dec 2006 A1
20060282071 Utley et al. Dec 2006 A1
20060287679 Stone Dec 2006 A1
20070021803 Deem et al. Jan 2007 A1
20070025919 Deem et al. Feb 2007 A1
20070027496 Pamis et al. Feb 2007 A1
20070032788 Edwards et al. Feb 2007 A1
20070043342 Kleinberger Feb 2007 A1
20070055328 Mayse et al. Mar 2007 A1
20070060954 Cameron et al. Mar 2007 A1
20070060990 Satake Mar 2007 A1
20070062545 Danek et al. Mar 2007 A1
20070066957 Demarais et al. Mar 2007 A1
20070074719 Danek et al. Apr 2007 A1
20070083194 Kunis et al. Apr 2007 A1
20070083197 Danek et al. Apr 2007 A1
20070083239 Demarais et al. Apr 2007 A1
20070093802 Danek et al. Apr 2007 A1
20070093809 Edwards et al. Apr 2007 A1
20070100390 Danaek et al. May 2007 A1
20070102011 Danek et al. May 2007 A1
20070106292 Kaplan et al. May 2007 A1
20070106296 Laufer et al. May 2007 A1
20070106337 Errico et al. May 2007 A1
20070106338 Errico May 2007 A1
20070106339 Errico et al. May 2007 A1
20070106348 Laufer May 2007 A1
20070112349 Danek et al. May 2007 A1
20070118184 Danek et al. May 2007 A1
20070118190 Danek et al. May 2007 A1
20070123922 Cooper et al. May 2007 A1
20070123958 Laufer May 2007 A1
20070123961 Danek et al. May 2007 A1
20070129720 Demarais et al. Jun 2007 A1
20070129760 Demarais et al. Jun 2007 A1
20070129761 Demarais et al. Jun 2007 A1
20070135875 Demarais et al. Jun 2007 A1
20070173899 Levin et al. Jul 2007 A1
20070191902 Errico et al. Aug 2007 A1
20070197896 Moll et al. Aug 2007 A1
20070203549 Demarais et al. Aug 2007 A1
20070225768 Dobak, III Sep 2007 A1
20070232896 Gilboa et al. Oct 2007 A1
20070239256 Weber et al. Oct 2007 A1
20070244479 Beatty et al. Oct 2007 A1
20070250050 Lafontaine Oct 2007 A1
20070255270 Carney Nov 2007 A1
20070255304 Roschak et al. Nov 2007 A1
20070265639 Danek et al. Nov 2007 A1
20070265687 Deem et al. Nov 2007 A1
20070267011 Deem et al. Nov 2007 A1
20070276362 Rioux et al. Nov 2007 A1
20080004596 Yun et al. Jan 2008 A1
20080021274 Bayer et al. Jan 2008 A1
20080021369 Deem et al. Jan 2008 A1
20080051839 Libbus et al. Feb 2008 A1
20080086107 Roschak Apr 2008 A1
20080097139 Clerc et al. Apr 2008 A1
20080097422 Edwards et al. Apr 2008 A1
20080097424 Wizeman et al. Apr 2008 A1
20080125772 Stone et al. May 2008 A1
20080147137 Cohen et al. Jun 2008 A1
20080154258 Chang et al. Jun 2008 A1
20080161801 Steinke et al. Jul 2008 A1
20080183248 Rezai et al. Jul 2008 A1
20080188912 Stone et al. Aug 2008 A1
20080188913 Stone et al. Aug 2008 A1
20080194956 Aldrich et al. Aug 2008 A1
20080208305 Rezai et al. Aug 2008 A1
20080213331 Gelfand et al. Sep 2008 A1
20080234564 Beatty et al. Sep 2008 A1
20080243112 DeNeve Oct 2008 A1
20080255449 Warnking et al. Oct 2008 A1
20080255642 Zarins et al. Oct 2008 A1
20080262489 Steinke Oct 2008 A1
20080275445 Kelly et al. Nov 2008 A1
20080302359 Loomas et al. Dec 2008 A1
20080306570 Rezai et al. Dec 2008 A1
20080312543 Laufer et al. Dec 2008 A1
20080312725 Penner Dec 2008 A1
20080319350 Wallace et al. Dec 2008 A1
20090018473 Aldrich et al. Jan 2009 A1
20090018538 Webster et al. Jan 2009 A1
20090030477 Jarrard Jan 2009 A1
20090036948 Levin et al. Feb 2009 A1
20090043301 Jarrard et al. Feb 2009 A1
20090043302 Ford et al. Feb 2009 A1
20090048593 Ganz et al. Feb 2009 A1
20090060953 Sandars Mar 2009 A1
20090062873 Wu et al. Mar 2009 A1
20090069797 Danek et al. Mar 2009 A1
20090076409 Wu et al. Mar 2009 A1
20090076491 Roschak et al. Mar 2009 A1
20090112203 Danek et al. Apr 2009 A1
20090124883 Wibowo et al. May 2009 A1
20090131765 Roschak et al. May 2009 A1
20090131928 Edwards et al. May 2009 A1
20090131930 Gelbart et al. May 2009 A1
20090143678 Keast et al. Jun 2009 A1
20090143705 Danek et al. Jun 2009 A1
20090143776 Danek et al. Jun 2009 A1
20090143831 Huston et al. Jun 2009 A1
20090155336 Rezai Jun 2009 A1
20090177192 Rioux et al. Jul 2009 A1
20090192505 Askew et al. Jul 2009 A1
20090192508 Laufer et al. Jul 2009 A1
20090204005 Keast et al. Aug 2009 A1
20090204119 Bleich et al. Aug 2009 A1
20090227885 Lowery et al. Sep 2009 A1
20090227980 Kangas et al. Sep 2009 A1
20090232850 Manack et al. Sep 2009 A1
20090248011 Hlavka et al. Oct 2009 A1
20090254079 Edwards et al. Oct 2009 A1
20090254142 Edwards et al. Oct 2009 A1
20090259274 Simon et al. Oct 2009 A1
20090275840 Roschak et al. Nov 2009 A1
20090275878 Cambier et al. Nov 2009 A1
20090281593 Errico et al. Nov 2009 A9
20090287087 Gwerder et al. Nov 2009 A1
20090306644 Mayse et al. Dec 2009 A1
20090318904 Cooper et al. Dec 2009 A9
20090319002 Simon Dec 2009 A1
20100003282 Deem et al. Jan 2010 A1
20100004648 Edwards et al. Jan 2010 A1
20100010564 Simon Jan 2010 A1
20100016709 Gilboa et al. Jan 2010 A1
20100042089 Soltesz et al. Feb 2010 A1
20100049031 Fruland et al. Feb 2010 A1
20100049186 Ingle et al. Feb 2010 A1
20100049188 Nelson et al. Feb 2010 A1
20100057178 Simon Mar 2010 A1
20100063495 Edwards et al. Mar 2010 A1
20100070004 Hlavka et al. Mar 2010 A1
20100076518 Hlavka et al. Mar 2010 A1
20100087783 Weber et al. Apr 2010 A1
20100087809 Edwards et al. Apr 2010 A1
20100094231 Bleich et al. Apr 2010 A1
20100114087 Edwards et al. May 2010 A1
20100116279 Cooper May 2010 A9
20100125239 Perry et al. May 2010 A1
20100130892 Warnking May 2010 A1
20100137860 Demarais et al. Jun 2010 A1
20100145427 Gliner et al. Jun 2010 A1
20100152835 Orr Jun 2010 A1
20100160906 Jarrard Jun 2010 A1
20100160996 Simon et al. Jun 2010 A1
20100174340 Simon Jul 2010 A1
20100179424 Warnking et al. Jul 2010 A1
20100185190 Danek et al. Jul 2010 A1
20100191089 Stebler et al. Jul 2010 A1
20100204689 Danek et al. Aug 2010 A1
20100222851 Deem et al. Sep 2010 A1
20100228318 Errico et al. Sep 2010 A1
20100241188 Errico et al. Sep 2010 A1
20100249873 Errico Sep 2010 A1
20100256629 Wylie et al. Oct 2010 A1
20100256630 Hamilton et al. Oct 2010 A1
20100268222 Danek et al. Oct 2010 A1
20100298905 Simon Nov 2010 A1
20100305463 Macklem et al. Dec 2010 A1
20100318020 Atanasoska et al. Dec 2010 A1
20100331776 Salahieh et al. Dec 2010 A1
20110004148 Ishii Jan 2011 A1
20110015548 Aldrich et al. Jan 2011 A1
20110028898 Clark, III et al. Feb 2011 A1
20110046432 Simon et al. Feb 2011 A1
20110060380 Gelfand et al. Mar 2011 A1
20110079230 Danek et al. Apr 2011 A1
20110093032 Boggs, II et al. Apr 2011 A1
20110098762 Rezai Apr 2011 A1
20110112400 Emery et al. May 2011 A1
20110112521 DeLonzor et al. May 2011 A1
20110118725 Mayse et al. May 2011 A1
20110125203 Simon et al. May 2011 A1
20110125213 Simon et al. May 2011 A1
20110130708 Perry et al. Jun 2011 A1
20110137284 Arora et al. Jun 2011 A1
20110144630 Loeb Jun 2011 A1
20110146673 Keast et al. Jun 2011 A1
20110146674 Roschak Jun 2011 A1
20110152855 Mayse et al. Jun 2011 A1
20110152967 Simon et al. Jun 2011 A1
20110152974 Rezai et al. Jun 2011 A1
20110166499 Demarais et al. Jul 2011 A1
20110166565 Wizeman et al. Jul 2011 A1
20110172655 Biggs et al. Jul 2011 A1
20110172658 Gelbart et al. Jul 2011 A1
20110178569 Pamis et al. Jul 2011 A1
20110184330 Laufer et al. Jul 2011 A1
20110190569 Simon et al. Aug 2011 A1
20110196288 Kaplan et al. Aug 2011 A1
20110202098 Demarais et al. Aug 2011 A1
20110224768 Edwards Sep 2011 A1
20110230701 Simon et al. Sep 2011 A1
20110230938 Simon et al. Sep 2011 A1
20110245756 Arora et al. Oct 2011 A1
20110251592 Biggs et al. Oct 2011 A1
20110257622 Salahieh et al. Oct 2011 A1
20110257647 Mayse et al. Oct 2011 A1
20110263960 Mitchell Oct 2011 A1
20110264086 Ingle Oct 2011 A1
20110270249 Utley et al. Nov 2011 A1
20110276107 Simon et al. Nov 2011 A1
20110276112 Simon et al. Nov 2011 A1
20110282229 Danek et al. Nov 2011 A1
20110282418 Saunders et al. Nov 2011 A1
20110301587 Deem et al. Dec 2011 A1
20110301664 Rezai Dec 2011 A1
20110301679 Rezai et al. Dec 2011 A1
20110306851 Wang Dec 2011 A1
20110306904 Jacobson et al. Dec 2011 A1
20110306997 Roschak et al. Dec 2011 A9
20110319958 Simon et al. Dec 2011 A1
20120004656 Jackson et al. Jan 2012 A1
20120015019 Pacetti et al. Jan 2012 A1
20120016256 Mabary et al. Jan 2012 A1
20120016358 Mayse et al. Jan 2012 A1
20120016363 Mayse et al. Jan 2012 A1
20120016364 Mayse et al. Jan 2012 A1
20120029261 Deem et al. Feb 2012 A1
20120029500 Jenson Feb 2012 A1
20120029512 Willard et al. Feb 2012 A1
20120029591 Simon et al. Feb 2012 A1
20120029601 Simon et al. Feb 2012 A1
20120041412 Roth et al. Feb 2012 A1
20120041509 Knudson et al. Feb 2012 A1
20120071870 Salahieh et al. Mar 2012 A1
20120078096 Krolik et al. Mar 2012 A1
20120083734 Ayres et al. Apr 2012 A1
20120089078 Deem et al. Apr 2012 A1
20120089138 Edwards et al. Apr 2012 A1
20120101326 Simon et al. Apr 2012 A1
20120101413 Beetel et al. Apr 2012 A1
20120109278 Sih May 2012 A1
20120143132 Orlowski Jun 2012 A1
20120143177 Avitall Jun 2012 A1
20120143179 Avitall Jun 2012 A1
20120143181 Demarais et al. Jun 2012 A1
20120157986 Stone et al. Jun 2012 A1
20120157987 Steinke et al. Jun 2012 A1
20120157988 Stone et al. Jun 2012 A1
20120157989 Stone et al. Jun 2012 A1
20120158101 Stone et al. Jun 2012 A1
20120165803 Bencini et al. Jun 2012 A1
20120184801 Simon et al. Jul 2012 A1
20120185020 Simon et al. Jul 2012 A1
20120191081 Markowitz Jul 2012 A1
20120191082 Markowitz Jul 2012 A1
20120197100 Razavi et al. Aug 2012 A1
20120197246 Mauch Aug 2012 A1
20120197251 Edwards et al. Aug 2012 A1
20120203067 Higgins et al. Aug 2012 A1
20120203216 Mayse et al. Aug 2012 A1
20120203222 Mayse et al. Aug 2012 A1
20120209118 Warnking Aug 2012 A1
20120209259 Danek et al. Aug 2012 A1
20120209261 Mayse et al. Aug 2012 A1
20120209296 Mayse et al. Aug 2012 A1
20120221087 Pamis et al. Aug 2012 A1
20120232436 Warnking Sep 2012 A1
20120245415 Emura et al. Sep 2012 A1
20120253442 Gliner et al. Oct 2012 A1
20120259263 Celermajer et al. Oct 2012 A1
20120259269 Meyer Oct 2012 A1
20120259326 Brannan et al. Oct 2012 A1
20120265280 Errico et al. Oct 2012 A1
20120289952 Utley et al. Nov 2012 A1
20120290035 Levine et al. Nov 2012 A1
20120294424 Chin et al. Nov 2012 A1
20120296329 Ng Nov 2012 A1
20120302909 Mayse et al. Nov 2012 A1
20120310233 Dimmer et al. Dec 2012 A1
20120316552 Mayse et al. Dec 2012 A1
20120316559 Mayse et al. Dec 2012 A1
20120330298 Ganz et al. Dec 2012 A1
20130012844 Demarais et al. Jan 2013 A1
20130012866 Deem et al. Jan 2013 A1
20130012867 Demarais et al. Jan 2013 A1
20130035576 O'Grady et al. Feb 2013 A1
20130123751 Deem et al. May 2013 A1
20130289555 Mayse et al. Oct 2013 A1
20130289556 Mayse et al. Oct 2013 A1
20130296647 Mayse et al. Nov 2013 A1
20130303948 Deem et al. Nov 2013 A1
20130310822 Mayse et al. Nov 2013 A1
20130345700 Hlavka et al. Dec 2013 A1
20140186341 Mayse Jul 2014 A1
20140236148 Hlavka et al. Aug 2014 A1
20140257271 Mayse et al. Sep 2014 A1
20140276792 Kaveckis et al. Sep 2014 A1
20150051597 Mayse et al. Feb 2015 A1
Foreign Referenced Citations (95)
Number Date Country
2419228 Aug 2004 CA
101115448 Jan 2008 CN
101115448 May 2010 CN
19529634 Feb 1997 DE
19952505 May 2001 DE
189329 Jun 1987 EP
286145 Oct 1988 EP
280225 Mar 1989 EP
286145 Oct 1990 EP
282225 Jun 1992 EP
0 643 982 Mar 1995 EP
908713 Apr 1999 EP
1 143 864 Oct 2001 EP
1 271 384 Jan 2003 EP
1 281 366 Feb 2003 EP
908150 May 2003 EP
1 326 548 Jul 2003 EP
1 326 549 Jul 2003 EP
768091 Jul 2003 EP
1 400 204 Mar 2004 EP
1297795 Aug 2005 EP
1 588 662 Oct 2005 EP
2659240 Jul 1997 FR
2233293 Jan 1991 GB
59167707 Sep 1984 JP
7289557 Nov 1995 JP
9047518 Feb 1997 JP
9243837 Sep 1997 JP
10026709 Jan 1998 JP
2053814 Feb 1996 RU
2091054 Sep 1997 RU
545358 Feb 1977 SU
8911311 Nov 1989 WO
9301862 Feb 1993 WO
9316632 Sep 1993 WO
9407446 Apr 1994 WO
9501075 Jan 1995 WO
9510322 Jan 1995 WO
9510322 Apr 1995 WO
9604860 Feb 1996 WO
9610961 Apr 1996 WO
9725917 Jul 1997 WO
9732532 Sep 1997 WO
9733715 Sep 1997 WO
9737715 Oct 1997 WO
9740751 Nov 1997 WO
9818391 May 1998 WO
9844854 Oct 1998 WO
9852480 Nov 1998 WO
9856234 Dec 1998 WO
9856324 Dec 1998 WO
9903413 Jan 1999 WO
9858681 Mar 1999 WO
9913779 Mar 1999 WO
9932040 Jul 1999 WO
9942047 Aug 1999 WO
9964109 Dec 1999 WO
0010598 Mar 2000 WO
0051510 Sep 2000 WO
0062699 Oct 2000 WO
0066017 Nov 2000 WO
0100114 Jan 2001 WO
0103642 Jan 2001 WO
0170114 Sep 2001 WO
0189526 Nov 2001 WO
0205720 Jan 2002 WO
0205868 Jan 2002 WO
0232333 Apr 2002 WO
0232334 Apr 2002 WO
03073358 Sep 2003 WO
03088820 Oct 2003 WO
2004078252 Sep 2004 WO
2004082736 Sep 2004 WO
2004101028 Nov 2004 WO
2005006963 Jan 2005 WO
2005006964 Jan 2005 WO
2006053308 May 2006 WO
2006053309 May 2006 WO
2006116198 Nov 2006 WO
2007058780 May 2007 WO
2007061982 May 2007 WO
2007092062 Aug 2007 WO
2007094828 Aug 2007 WO
2007143665 Dec 2007 WO
2008005953 Jan 2008 WO
2008024220 Feb 2008 WO
2008051706 May 2008 WO
2008063935 May 2008 WO
2009009236 Jan 2009 WO
2009015278 Jan 2009 WO
2009082433 Jul 2009 WO
2009126383 Oct 2009 WO
2009137819 Nov 2009 WO
2010110785 Sep 2010 WO
2011060200 May 2011 WO
Non-Patent Literature Citations (203)
Entry
Bradley et al., “Effect of vagotomy on the breathing pattern and exercise ability in emphysematous patients,” Clinical Science 62:311-319, 1982.
Breekveldt-Postma et al., “Enhanced persistence with tiotropium compared with other respiratory drugs in COPD,” Respiratory Medicine 101:1398-1405,2007.
Chemyshova et al., “The Effect of Low-Energy Laser Radiation in the Infrared Spectrum on Bronchial Patency in Children With Bronchial Asthma,” Vopr Kurortol, Fizioter Lech Fiz Kult 2:11-14, 1995.
Chumakov et al., “Morphologic studies of bronchial biopsies in chronic bronchitis before and after treatment,” Arkh Patol57(6):21-25, 1995. (See English Abstract on last page.).
Dimitrov-Szokodi et al., “Lung Denervation in the Therapy oflntractable Bronchial Asthma,” J. Thoracic Surg. 33(2):166-184, Feb. 1957.
Donohue et al., “A 6-Month, Placebo-Controlled Study Comparing Lung Function and Health Status Changes in COPD Patients Treated With Tiotropium or Salmeterol,” Chest 122:47-55, 2002.
Friedman et al., “Healthcare Costs with Tiotropium Plus Usual Care versus Usual Care Alone Following 1 Year of Treatment in Patients with Chronic Obstructive Pulmonary Disorder (COPD),” Pharmacoeconomics 22(11):741-749, 2004.
George et al., “Factors Associated With Medication Nonadherence in Patients With COPD,” Chest 128:3198-3204,2005.
Korochkin et al., “Use of a Helium-Neon Laser in Combined Treatment of Bronchial Asthma,” New Developments in Diagnostics and Treatment, 1990, 9 pgs.
Lokke et al., “Developing COPD: a 25 year follow up study of the general population,” Thorax 61:935-939, 2006.
Maesen et al., “Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD),” Eur. Respi. J. 8:1506-1513, 1995.
Maltais et al., “Improvements in Symptom-Limited Exercise Performance Over 8 h With Once-Daily Tiotropium in Patients With COPD,” Chest 128:1168-1178, 2005.
O'Connor et al., “Prolonged Effect ofTiotropium Bromide on Methacholine-induced Bronchoconstriction in Asthma,” Am. J. Respir. Crit. Care Med. 154:876-880, 1996.
Peters et al., “Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled Asthma,” New England Journal of Medicine 363(18):1715-1726, Oct. 28, 2010.
Polosukhin, “Dynamics of the ultrastructural changes in blood and lymphatic capillaries ofbronchi in inflammation and following endobronchial laser therapy,” Virchows Arch 431:283-390, 1997.
Polosukhin, “Regeneration of bronchial epithelium on chronic inflammatory changes under laser treatment,” Path. Res. Pract. 192(9):909-918, 1996.
Polosukhin, “Ultrastructural study of the destructive and repair processes in pulmonary inflammation and following endobronchial laser therapy,” Virchows Arch 435:13-19, 1999.
Tashkin et al., “Long-term Treatment Benefits With Tiotropium in COPD Patients With and Without Short-term Bronchodilator Responses,” Chest 123: 1441-1449, 2003.
Vincken et al., “Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium,” Eur. Respir. J. 19: 209-216, 2002.
Wagner et al., “Methacholine causes reflex bronchoconstriction,” J. Appl. Physiol. 86:294-297, 1999.
Abbott, “Present Concepts Relative to Autonomic Nerve Surgery in the Treatment of Pulmonary Disease,” American Journal of Surgery 90:479-489, 1955.
Ahnert-Hilger et al., “Introduction of Macromolecules into Bovine Adrenal-Medullary Chromaffin Cells and Rat Pheochromocytoma Cells (PC12) by Permeabilization with Streptolysin O: Inhibitory Effect of Tetanus Toxin on Catecholamine Secretion,” J Neurochem 52(6):1751-1758, Jun. 1989.
Babichev et al., “Clinico-morphological comparisons in patients with bronchial asthma aftet denervation of the lungs,” Sov Med. 12:13-16, 1985.
Babichev et al., “Long-term results of surgical treatment of bronchial asthma based on adaptive response,” Khirurgiia (Mask) 4:5-11, 1993.
Babichev et al., “Partial deneration of the lungs in bronchial asthma,” Khirurgiia (Mask) 4:31-35, 1985.
Barlaw, “Surgical Treatment of Asthma,” Postgrad Med. Journal 25:193-196, 1949.
Bester et al., “Recovery of C-Fiber-Induced Extravasation Following Peripheral Nerve Injury in the Rat,” Experimental Neurology 154:628-636, 1998.
Bigalke et al., “Clostridial Neurotoxins,” Handbook of Experimental Pharmacology (Aktories, K, and Just, I., eds) 145:407-443, 2000.
Bittner et al., “Isolated Light Chains of Botulinum Neurotoxins Inhibit Exocytosis,” The Journal of Biological Chemistry 264(18):10354-10360, 1989.
Blindt et al., “Development of a New Biodegradable Intravascular Polymer Stent with Simultaneous Incorporation ofBioactive Substances,” The International Journal of Artificial Organs 22(12):843-853, 1999.
Brody et al., “Mucociliary clearance after lung denervation and bronchial transection,” J Applied Physiology 32(2):160-164, 1972.
Buzzi, “Diphtheria Toxin Treatment of Human Advanced Cancer,” Cancer Research 42:2054-2058, 1982.
Canning et al., “Reflex Mechanisms in Gastroesophageal Reflux Disease and Asthma,” The American Journal of Medicine 115(3A):45S-48S, 2003.
Canning et al., “Reflex Mechanisms in Gastroesophageal Reflux Disease and Asthma,” Am J Med. 115(Suppl3A):45S-48S, 2003. (Abstract only.).
Canning, “Reflex regulation of airway smooth muscle tone,” J Appl. Physiol. (1OJ):971-985,2006.
Chaddock et al. “Expression and Purification of Catalytically Active, Non-Toxic Endopeptidase Derivatives of Clostridium botulinum Toxin Type A,” Protein Expression and Purification 25(2):219-228, Jul. 2002.
Chang, “Cell poration and cell fusion using an oscillating electric field,” Biophys. J 56:641 652, 1989.
Chemyshova et al., “The Effect of Low-Energy Laser Radiation in the Infrared Spectrum Oil Bronchial Patency in Children with Bronchial Asthma,” Vopr Kurortol Fizioter Lech Fiz Kult 2:11-14, 1995. (+English translation, 6 pages.).
Chumakov et al., “Morphologic Studies of Bronchial Biopsies in Chronic Bronchitis Before and After Treatment,” Arkh. Patol. 57(6):21-25, 1995. (+English abstract and translation, 8 pages.).
Crimi et al., “Protective effects of inhaled ipratropium bromide on bronchoconstriction induced by adenosine and methacholine in asthma,” Eur Respir J 5:560-565, 1992.
De Paiva et al., “Light chain of botulinum neurotoxin is active in mammalian motor nerve terminals when delivered via liposomes,” FEES Lett. 17:277(1-2): 171-174, Dec. 1990.
Feshenko et al., “Clinico-morphological comparisons in the laser therapy of chronic bronchitis patients,” Lik Sprava. (10-12):75-79, 1993. (+English abstract, 1 Page.).
Gelb et al., “Laser in treatment of lung cancer,” Chest 86(5):662-666, 1984.
Gerasin et al., “Endobronchial electrosurgery,” Chest 93:270-274, 1988.
Gibson et al., “Gastroesophageal Reflux Treatment for Asthma in Adults and Children,” Cochrane Database Syst. Rev. 2:CD001496, 2003. (Abstract only.).
Glanville et al., “Bronchial responsiveness after human heart-lung transplantation,” Chest 97(6):1360-1366, 1990.
Glanville et al., “Bronchial responsiveness to exercise after human cardiopulmonary transplantation,” Chest 96(2):81-286, 1989.
Gosens et al., “Muscarinic receptor signaling in the pathophysiology of asthma and COPD,” Respiratory Research 7(73):1-15, 2006.
Groeben et al. “High Thoracic Epidural Anesthesia Does Not Alter Airway Resistance and Attenuates the Response to an Inhalational Provocation Test in Patients with Bronchial Hyperreactivity,” Anesthesiolozy 81(4):868-874, 1994.
Guarini et al., “Efferent Vagal Fibre Stimulation Blunts Nuclear Factor-kB Activation and Protects Against Hypovolemic Hemmorrhagic Shock,” Circulation 107:1189-1194, 2003.
Guzman et al., “Bioeffects Caused by Changes in Acoustic Cavitation Bubble Density and Cell Concentration: A Unified Explanation Based on Cell-to-Bubble Ratio and Blast Radius,” Ultrasound in Med. & Biol. 29(8): 1211-1222, 2003.
Hainsworth et al., “Afferent lung denervation by brief inhalation of steam,” Journal of Applied Physiology (34)5: 708-714, 1972.
Harding, “Recent Clinical Investigations Examining the Association of Asthma and Gastroesophageal Reflux,” Am J Med. 115(Suppl3A):39S-44S, 2003. (Abstract only.).
Hiraga, “Experimental surgical therapy of bronchial asthma. The effect of denervation in dogs,” Nihon Kyobu Shikkan Gakkai Zasshi 19(1):46-56, 1981.
Hoffmann et al., “Inhibition of Histamine-Induced Bronchoconstriction in Guinea Pig and Swine by Pulsed Electrical Vagus Nerve Stimulation,” Neuromodulation: Technology at the Neural Inter{ace: 1-9, 2009.
Hooper et al., “Endobronchial electrocautery,” Chest 87(6):12-714, 1985.
Ivanyuta OM, et al., “Effect of Low-Power Laser Irradiation of Bronchia Mucosa on the State of Systemic and Local Immunity in Patients with Chronic Bronchitis,” Problemy Tuberkuleza 6:26-29, 1991.
Jammes et al., “Assessment of the Pulmonary Origin of Bronchoconstrictor Vagal Tone,” J Physiol. 291: 305-316, 1979.
Jiang et al., “Effects of Antireflux Treatment on Bronchial Hyper-responsiveness and Lung Function in Asthmatic Patients with Gastroesophageal Reflux Disease,” World J Gastroenterol. 9:1123-1125, 2003. (Abstract only.).
Karashurov et al., “Electrostimulation in the therapy of bronchial asthma,” Klin Med (Mask) 79(11):38-41, 2001.
Karashurov et al., “Radiofrequency electrostimulation of carotid sinus nerves for the treatment ofbronchial asthma,” Khirurgiia (Mask) 12:2-6, 1999.
Khmel'kova et al., “Does laser irridation affect bronchial obstruction?,” Probl Tuberk 3:41-42, 1995. (Abstract only.).
Khoshoo et al., “Role of Gastroesophageal Reflux in Older Children with Persistent Asthma,” Chest 123:1008-1013,2003. (Abstract only.).
Kiljander, “The Role ofProton Pump Inhibitors in the Management of Gastroesophageal Reflux Disease-Related Asthma and Chronic Cough,” Am J Med. 115(Suppl3A):65S-71S, 2003. (Abstract only.).
Kistner et al., “Reductive Cleavage of Tetanus Toxin and Botulinum Neurotoxin A by the Thioredoxin System from Brain,” Naunyn-Schmiedebergs Arch Pharmacal 345(2):227-234, Feb. 1992.
Kletskin et al., “Value of assessing the autonomic nervous system in bronchial asthma in selecting the surgical treatment method,” Khirurgiia (Mask) 7:91-95, 1987.
Kliachkin et al., “Bronchoscopy in the treatment of bronchial asthma of infectious allergic origin,” Ter Arkh 54(4):76-79, 1982.
Korpela et al., “Comparison of Tissue Reactions in the Tracheal Mucosa Surrounding a Bioabsorbable and Silicone Airway Stents,” Annals of Thoracic Surgery 66:1772-1776, 1998.
Kozaki et al., “New surgical treatment of bronchial asthma—denervation of the hilus pulmonis (2),” Nippon Kyobu Geka Gakkai Zasshi 22(5):465-466, 1974.
Kreitman, “Taming ricin toxin,” Nature Biotechnology 21:372-374,2003.
Kuntz, “The Autonomic Nervous System in Relation to the Thoracic Viscera,” Chest 10:1-18, 1944.
Lennerz et al., “Electrophysiological characterization of vagal afferents relevant to mucosal nociception in the rat upper oesophagus,” J Physiol. 582(1):229-242, 2007.
Levin, “The Treatment ofBronchial Asthma by Dorsal Sympathectomy,” Annals of Surgery 102(2):161-170, 1935.
Liou et al., “Causative and Contributive Factors to Asthmas Severity and Patterns of Medication Use in Patients Seeking Specialized Asthma Care,” Chest 124:1781-1788,2003. (Abstract only.).
Magnussen et al., “Effect ofInhaled Ipratropium Bromide on the Airway Response to Methacholine, Histamine, and Exercise in Patients with Mild Bronchial Asthma,” Respiration 59:42-47, 1992.
Mathew et al., “Gastro-oesophageal reflux and bronchial asthma: current status and future directions,” Postgrad Med. J 80:701-705,2004.
McKay et al., “Autocrine regulation of asthmatic airway inflammation: role of airway smooth muscle,” Respir Res 3(11):1-13, 2002.
Mehta et al., “Effect of endobronchial radiation therapy on malignant bronchial obstruction,” Chest 97(3):662-665, 1990.
Meshalkin et al., “Partial denervation of the pulmonary hilus as one of the methods of surgical treatment of bronchial asthma,” Grudn Khir 1:109-111, 1975.
Moore, Keith L., Clinically Oriented Anatomy, 2nd ed., Williams & Wilkins, Baltimore, 1985, pp. 85 and 87. (Abstract only.).
Netter, Frank H., The Ciba Collection of Medical Illustrations: vol. 7, Respiratory System, CIBA-GEIGY Corporation, West Caldwell, 1979, p. 23, section 1. (Abstract only.
Ochs, Matthias et al., Fisherman, Alfred P., et al. (eds), Functional Design of the Human Lungfor Gas Exchange, 4th ed., McGraw Hill Medical, New York, 2008, Chap. 2, “Fisherman's Pulmonary Diseases and Disorders.” (Abstract only.).
Ovcharenko et al., “Endobronchial use oflow-frequency ultrasound and ultraviolet laser radiation in the complex treatment of patients with suppurative bronchial diseases,” Probl Tuberk 3:40-42, 1997. (Abstract only.).
Overholt, “Glomectomy for Asthma,” Dis Chest 40:605-610, 1961.
Petrou, et al., “Bronchoscopic Diathermy Resection and Stent Insertion: a Cost Effective Treatment for Tracheobronchial Obstruction,” Thorax 48:1156-1159, 1993.
Polosukhin, “Dynamics of the ultrastructural changes in blood and lymphatic capillaries of bronchi in inflammation and following endobronchial laser therapy,” Virchows Arch. 431:283-290, 1997.
Polosukhin, “Regeneration of Bronchial Epithelium on Chronic Inflammatory Changes Under Laser Treatment,” Path. Res. Pract. 192:909-918, 1996.
Polosukhin, “Ultrastructural study of the destructive and repair processes in pulmonary inflammation and following endobronchial laser therapy,” Virchows Arch. 435:13-19, 1999.
Polosukhin, “Ultrastructure of the Blood and Lymphatic Capillaries of the Respiratory Tissue During Inflammation and Endobronchial Laser Therapy,” Ultrastructural Pathology 24:183-189, 2000.
Provotorov VM, et al., “Clinical Efficacy of Treatment of Patients with Non-Specific Pulmonary Diseases by Using Low-Power Laser Irradiation and Performing Intrapulmonary Drug Administration,” Terapevichesky Arkhiv 62:18-23, 1991.
Raj, “Editorial,” Pain Practice 4(1S): S1-S3, 2004.
Ramirez et al., “Sympathetomy in Bronchial Asthma,” J A.M. A. 84 (26):2002-2003, 1925.
Rienhoff et al., “Treatment oflntractable Bronchial Asthma by Bilateral Resection of the Posterior Pulmonary Plexus,” Arch Surg 37(3):456-469, 1938.
Savchenko et al., “Adaptation of regulatory physiological systems in surgical treatment of patients with bronchial asthma,” Klin Med (Mask) 74(7):38-39, 1996.
Sengupta, “Part 1 Oral cavity, pharynx and esophagus—Esophageal sensory physiology,” GI Motility online:17 pages, 2006.
Sepulveda et al., “Treatment of Asthmatic Bronchoconstriction by Percutaneous Low Voltage Vagal Nerve Stimulation: Case Report,” Internet Journal of Asthma, Allergy, and Immunolo;zy 7(2):3 pages, 2009.
Shaari et al., “Rhinorrhea is Decreased in Dogs After Nasal Application of Botulinum.Toxin,” Otolaryngol Head Neck Surg 112(14):566-571, 1992.
Sheski FD, et al., “Cryotherapy, Electrocautery, and Brachytherapy,” Clinics in Chest Medicine 20(1):123-138, Mar. 1999.
Sil'vestrov et al., “The Clinico-Pathogenetic Validation and Efficacy of the Use ofLow-Energy Laser Irradiation and Glucocorticoids in the Treatment of Bronchial Asthma Patients,” Ter Arkh 63(11), 87-92, 1991.
Simonsson et al., “Role of Autonomic Nervous System and the Cough Reflex in the Increased Responsiveness of Airways in Patients with Obstructive Airway Disease,” The Journal ofClinical Investigation 46(11): 1812-1818, 1967.
Simpson et al., “Isolation and Characterization of the Botulinum Neurotoxins,” Methods Enzymol165:76-85, 1988.
Smakov, “Denervation of the lung in the treatment ofbronchial asthma,” Khirurgiia (Mask) 9:117-120, 1982.
Smakov, “Pathogenetic substantiation of lung denervation in bronchial asthma and it's indications,” Khirurgiia (Mask) 2:67-69, 1999.
Smakov, “Prognostication of the effect of therapeutic bronchoscopy in patients with bronchial asthma according to the state oflocal immunity,” Klin Med (Mask) 73(5):76-77, 1995.
Sontag et al., “Asthmatics with Gastroesophageal Reflux: Long-term Results of a Randomized Trial of Medical and Surgical Antireflux Therapies,” Am J Gastroenterol. 98:987-999, 2003. (Abstract only.).
Stein, “Possible Mechanisms of Influence of Esophageal Acid on Airway Hyperresponsiveness,” Am J Med. 115(Suppl3A):55S-59S, 2003. (Abstract only.).
Sundaram et al., “An Experimental and Theoretical Analysis ofUltrasound-Induced Permeabilization of Cell Membranes,” Biophysical Journal84:3087-3101, 2003.
Takino et al., “Surgical Removal of the Carotid Body and its Relation to the Carotid Chemoreceptor and Baroreceptor Reflex in Asthmatics,” Dis Chest 47:129-138, 1965.
Tsugeno et al., “A Proton-Pump Inhibitor, Rabeprazole, Improves Ventilatory Function in Patients with Asthma Associated with Gastroesophageal Reflux,” Scand J Gastroenterol. 38:456-461, 2003. (Abstract only.).
Tsuji et al., “Biodegradable Stents as a Platform to Drug Loading,” International Journal of Cardiovascular Interventions 5:13-16, 2003.
Unal et al., “Effect of Botulinum Toxin Type A on Nasal Symptoms in Patients with Allergic Rhinitis: A Double-blind, Placebo-controlled Clinical Trial,” Acta Oto-Laryngologica 123(9):1060-0163, Dec. 2003.
Van Boxem TJM, et al., “Tissue Effects ofBronchoscopic Electrocautery,” Chest 117(3):887-891, Mar. 1999.
van der Velden et al., “Autonomic Innervation of Human Airways: Structure, Function, and Pathophysiology in Asthma,” Neuroimmunomodulation 6:145-159, 1999.
Verhein et al., “Neural Control of Airway Inflammation,” Current Allergy and Asthma Reports 9:484-490, 2009.
Vorotnev et al., “Treatment of Patients with Chronic Obstructive Bronchitis Using Low Energy Laser at a General Rehabilitation Center,” Therapeutic Archive 3:17-19, 1997. (+English translation, 4 pages.).
Wahidi et al., “State of the Art: Interventional Pulmonology,” Chest 131:261-274, 2007.
Weaver, “Electroporation: A General Phenomenon for Manipulating Cells and Tissues,” Journal ofCellular Biochemistry 51(4):426-435, Apr. 1993.
Wirtz et al., “Bilateral Lung Transplantation for Severe Persistent and Difficult Asthma,” The Journal of Heart and LunTransplantation 24(10):1700-1703, 2005.
Laufer, “Method and Apparatus for Treating Smooth Muscles in the Walls of Body Conduits,” U.S. Appl. No. 09/095,323, filed Jun. 10, 1998,25 pages.
Application and File History for U.S. Appl. No. 14/541,931, filed Nov. 11, 2010, inventors Mayse et al., issued as U.S. Pat. No. 8,911,439 on Dec. 16, 2014.
Global Strategy for Asthma Management and Prevention, 2002, 192 Pages Total.
James, et al., “The Mechanics of Airway Narrowing in Asthma,” Am. Rev. Respir. Dis., 1989, 139, 242-246.
Janssen L. J., “Asthma therapy: how far have we come, why did we fail and where should we go next?,” Eur Respir J, 2009, 33, pp. 11-20.
Kitamura S., “Color Atlas of Clinical Application ofFiberoptic Bronchoscopy,” 1990, Year Book Medical Publishers, 17.
Kraft M., “The distal airways: are they Important in asthma?,” European Respiratory, 1999, 1403-1417.
Notice of final Rejection, Japanese Patent Application No. 2000-553172, dated Sep. 2, 2008, 5 pages.
PCT International search report for application No. PCT/US00/05412 mailed on Jun. 20, 2000, 2 pages.
PCT International search report for application No. PCT/US00/18197 mailed on Oct. 3, 2000, 1 page.
PCT International search report for application No. PCT/US00/28745 mailed on Mar. 28, 2001, 6 pages.
PCT International search report for application No. PCT/USO1/32321 mailed on Jan. 18, 2002, 2 pages.
PCT International search report for application No. PCT/US98/03759 mailed on Jul. 30, 1998, 1 page.
PCT International search report for application No. PCT/US98/26227 mailed on Mar. 25, 1999, 1 page.
PCT International search report for application No. PCT/US99/00232 mailed on Mar. 4, 1999, 1 page.
PCT International search report for application No. PCT/US99/12986 mailed on Sep. 29, 1999, 1 page.
Peter K. Jeffery, “Remodeling in Asthma and Chronic Obstructive Lung Disease,” American Journal ofRespiratory and Critical Care Medicine, 2001, 164 (10), 13516.
Seow C. Y., et al. “Signal Transduction in Smooth Muscle Historical perspective on airway smooth muscle: the saga of a frustrated cell,” J Appl Physiol, 2001, 91, 938-952.
Stephanie Ashore, “Airway Smooth Muscle in Asthma—Not Just More of the Same.” N Enol J Med, 2004,351 (6), 531-532.
UNSW Embryo—Respiratory System [online]. Embryology, 2007, [retrieved on Dec. 10, 2007]. Retrieved from the internet: (URL: http://embryology.med.unsw.edu.au/Refer/respire/select.htm).
Wayne Mitzner, “Airway Smooth Muscle the appendix of the Lung,” American Journal of Respiratory and Critical Care Medicine, 2004, 169, 787-790.
Wayne Mitzner, “Bronchial Thermoplasty in Asthma,” Allergology International, 2006, 55, 225-234.
Non-Final Office Action for U.S. Appl. No. 11/398,353; Mailed on Aug. 31, 2009; 7 pages.
Non-Final Office Action for U.S. Appl. No. 11/398,353; Mailed on Apr. 27, 2010; 8 pages.
Simon R. Johnson et al., Synthetic Functions of Airway Smooth Muscle in Asthma, Trends Pharmacal. Sci., Aug. 1997, 18(8), 288-292.
Macklem P.T., Mechanical Factors Determining Maximum Bronchoconstriction, European Respiratory Journal, Jun. 1989, 6, 516s-519s.
James C. Hogg, The Pathology of Asthma, APMIS, Oct. 1997, 105(10), 735-745.
Dierkesmann et al., Indication and Results of Endobronchial Laser Therapy, Lung, 1990, 168, 1095-1102.
Netter F.H., Respiratory System: A Compilation of Paintings Depicting Anatomy and Embryology, Physiology, Pathology, Pathophysiology, and Clinical Features and Treatment of Diseases, In the CIBA Collection of Medical Illustrations M.B. Divertie, ed., Summit New Jersey, 1979, vol. 7, 119-135.
Provotorov et al.; The Clinical Efficacy of Treating Patients with Nonspecific Lung Disease by Using Low-energy Laser Irradiation and Intrapulmonary Drug Administration, ISSN: 0040-3660., Terapevticheskii Arkhiv (USSR), 1991, 63 (12), 18-23.
Wiggs B.R. et al., On the Mechanism of Mucosal Folding in Normal and Asthmatic Airways, J. Appl. Physiol., Dec. 1997, 83(6), 1814-1821.
An, S. S. et al., Airway smooth muscle dynamics; a common pathway of airway obstruction in asthma, European Respiratory Journal, 2007, vol. 29, No. 5, pp. 834-860.
Bel, E, H., Hot Stuff: Bronchial Thermoplasty for Asthma, American Journal of Respiratory and Critical Care Medicine, 2006, vol. 173, pp. 941-942.
Brown, R. H. et al., In vivo evaluation of the effectiveness of bronchial thermoplasty with computed tomography. Journal of Applied Physiology, 2005, vol. 98, pp. 1603-1606.
Chhajed, P., Will There be a Role for Bronchoscopic Radiofrequency Ablation?, 2005, J Bronchol, vol. 12, No. 3, p. 184.
Cox, G., et al, . Early Clinical Experience With Bronchial Thermoplasty for the Treatment of Asthma, 2002, p. 1068.
Cox, G. et al., Asthma Control During the Year After Bronchial Thermoplasty, The New England Journal of Medicine, Mar. 29, 2007, vol. 356, No. 13, pp. 1327-1337.
Cox. G. et al., Bronchial Thermoplasty: One-Year Update, American Thoracic Society Annual Meeting, 2004, p. 1.
Cox, G., et al., Development of a Novel Bronchoscope Therapy for Asthma, Journal of Allergy and Clinical Immunology, 2003, p. 1.
Cox, G., et al., Bronchial Thermoplasty for Asthma, American Journal of Respiratory and Critical Care Medicine, 2006, vol. 173, pp. 965-969.
Cox, G., et al., Bronchial Thermoplasty: Long-Term Follow-up and Patient Satisfaction, 2004, p. 1.
Cox, G., et al., Radiofrequency ablation of airway smooth muscle for sustained treatment of asthma: preliminary investigations, European Respiratory Journal, 2004, 24, pp. 659-663.
Cox, G., et al., Clinical Experience with Bronchial Thermoplasty for the Treatment of Asthma, 2003, Chest 124, p. 106S.
Cox, G., et al., Impact of bronchial thermoplasty on asthma status: interim results from the AIR trial, 2006, European Respiratory Society Annual. Meeting, Munich, Germany, p. 1.
Danek, C. J., et al., Bronchial thermoplasty reduces canine airway responsiveness to local methacholine challenge, 2002, American Thoracic Society Annual Meeting, p. 1.
Danek, C. J., et al., Asthma Intervention Research (AIR) Trial Evaluating Bronchial Thermoplasty™; Early Results, 2002, American Thoracic Society Annual Meeting, p. 1.
Danek, C. J., et al., Reduction in airway hyperesponsiveness to methacholine by the application ofRF energy in dogs, J Appl Physiol, 2004, vol. 97, pp. 1946-1933.
Solway, J. et al., Airway Smooth Muscle as a Target for Asthma Therapy, The New England Journal of Medicine, Mar. 29, 2007, 356(13), pp. 1367-1369.
Lavioletts, et al. Asthma Intervention Research (AIR) Trial: Early Safety Assessment of Bronchial Thermoplasty, 2004, p. 1.
Leff et al., Bronchial Thermoplasty Alters Airway Smooth Muscle and Reduces Responsiveness in Dogs; A Possible Procedure for the Treatment of Asthma, American Thoracic Society Annual Meeting, 2002, p. 1.
Lim, E.E. et al., Botulinum Toxin: A Novel Therapeutic Option for Bronchial Asthma?, Medical Hypotheses, 2006, vol. 66, pp. 915-919.
Lombard, et al, Histologic Effects ofBronchial Thermoplasty of Canine and Human Airways, American Thoracic Society Annual Meeting, 2002, p. 1.
Mayse, M. et al., Clinical Pearls for Bronchial Thermoplasty, J Bronchol, Apr. 2007, vol. 14, No. 2, pp. 115-123.
Miller. J.D. et al., A Prospective Feasibility Study of Bronchial Thermoplasty in the Human Airway. 2005. vol. 127, No. 6 pp. 1999-2006.
Miller, J.D. et al., Bronchial Thermoplasty is Well Tolerated by Non-Asthmatic Patients Requiring Lobectomy, 2002, American Thoracic Society Annual Meeting, p. 1.
Rubin, et al., Bronchial Thermoplasty improves Asthma Status of Moderate to Severe Persistent Asthmatics Over and Above Current Standard-of-Care, 2006, American College of Chest Physicians, 2 pages.
Sterk, P. J., Heterogeneity of Airway Hyperresponsiveness: Time for Unconventional, but Traditional Studies, 2004, The American Pshychoiogical Society, pp. 2017-2018.
Wilson, S. R. et al., Global assessment after bronchial thermoplasty: the patient's perspective, Journal of Outcomes Research, 2006, vol. 10, pp. 37-46.
Toma, T. P., Brave New World for Interventional Bronchoscopy, 2005, Thorax, vol. 60, pp. 180-181.
Trow, T., Clinical Year in Review I, proceedings of the American Thoracic Society, 2006, vol. 3, pp. 553-556.
Wizeman, et al., A Computer Model of Thermal Treatment of Airways by Radiofrequency (RF) Energy Delivery, 2007, American Thoracic Society Annual Meeting, p. 1.
Shesterina. M. V. et al., Effect of laser therapy on immunity in patients with bronchial asthma and pulmonary tuberculosis, 1993, pp. 23-26.
Evis Exera Bronchovideoscope Brochure, Olympus BF-XT160, Olympus, Jun. 15, 2007, 2 pages.
Accad, M., “Single-Step Renal Denervation With the OneShot™ Ablation System,” presentation at the Leipzig Interventional Course 2012 in Leipzig, Germany, Jan. 26, 2012, 11 pages.
Bertog, S., “Covidien-Maya: OneShot™,” presentation at the 2012 Congenital & Structural Interventions Congress in Frankfurt, Germany, Jun. 28, 2012, 25 pages.
Rocha-Singh, K.J., “Renal Artery Denervation: A Brave New Frontier,” Endovascular Today, Feb. 2012, pp. 45-53.
Wilson, K.C., et al., “Flexible Bronchoscopy: Indications and Contraindications,” UpToDate, Nov. 12, 2010 <www.uptodate.com> [retrieved Sep. 30, 2012], 15 pages.
Gaude, G.S., “Pulmonary Manifestations of Gastroesophageal Reflux Disease,” Annals of Thoracic Medicine 4(3):115-123, Jul.-Sep. 2009.
Awadh, N., et al. “Airway Wall Thickness in Patients With Near Fatal Asthma and Control Groups: Assessment With High Resolution Computed Tomographic Scanning,” Thorax 53:248-253, 1998.
Castro, M., et al., “Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe Asthma: A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Trial,” American Journal of Respiratory and Critical Care Medicine 181: 116-124, 2010.
Martin, N., et al., “Bronchial Thermoplasty for the Treatment of Asthma,” Current Allergy and Asthma Reports 9(1):88-95, Jan. 2009.
McEvoy, C.E., et al., “Changing the Landscape: Bronchial Thermoplasty Offers a Novel Approach to Asthma Treatment,” Advance for Managers of Respiratory Care, pp. 22,24-25, Oct. 2007.
Michaud, G., et al., “Positioned for Success: Interest in Diagnostic and Therapeutic Bronchoscopy is Growing,” Advance for Managers of Respiratory Care, pp. 40, 42-43, Jul./Aug. 2008.
O'Sullivan, M.P., et al., “Apoptosis in the Airways: Another Balancing Act in the Epithelial Program,” American Journal of Respiratory Cell and Molecular Biology 29:3-7, 2003.
Pavord, I.D., et al., “Safety and Efficacy of Bronchial Thermoplasty in Symptomatic, Severe Asthma,” American Journal of Respiratory and Critical Care Medicine 176:1185-1191, 2007.
Tschumperlin, D.J., et al., “Chronic Effects of Mechanical Force on Airways,” Annual Review of Physiology 68: 563-83, 2006.
Tschumperlin, D.J., et al., “Mechanical Stimuli to Airway Remodeling,” American Journal of Respiratory and Critical Care Medicine 164:S90-S94, 2001.
Wechsler, M.E., “Bronchial Thermoplasty for Asthma: A Critical Review of a New Therapy,” Allergy and Asthma Proceedings 29(4):1-6, Jul.-Aug. 2008.
Co-Pending U.S. Appl. No. 13/523,223, filed Jun. 14, 2012, Edwin J. Hlavka et al.
Preliminary Amendment and Response to Restriction Requirement filed Oct. 22, 2012, in co-pending U.S. Appl. No. 13/523,223, filed Jun. 14, 2012, Edwin J. Hlavka et al.
Co-Pending U.S. Appl. No. 12/372,607, filed Feb. 17, 2009, Edwin J. Hlavka et al.
Amendment After Allowance filed Sep. 17, 2012, in co-pending U.S. Appl. No. 12/372,607, filed Feb. 17, 2009, Edwin J. Hlavka et al.
Montaudon, M., et al., “Assessment of bronchial wall thickness and lumen diameter in human adults using multi-detector computed tomography: comparison with theoretical models,” J. Anat. 211:579-588, 2007.
Urologix, Inc., “CTC Advance™ Instructions for Use,” Targis® System Manual, 2010, 8 pages.
Urologix, Inc., “Cooled ThermoTherapy™,” 2012, retrieved on Mar. 3, 2005 from URL=http://www.urologix.com/cllinicians/cooled-thermotherapy.php, 2 pages.
Related Publications (1)
Number Date Country
20150190193 A1 Jul 2015 US
Provisional Applications (1)
Number Date Country
61260350 Nov 2009 US
Continuations (1)
Number Date Country
Parent 12944666 Nov 2010 US
Child 14541931 US